[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 113
1. Khoo JJ, Alwi RI, Abd-Rahman I: Myoid hamartoma of breast with chondroid metaplasia: a case report. Malays J Pathol; 2009 Jun;31(1):77-80
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.
  • Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.
  • Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.
  • We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.
  • The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.
  • The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694319.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


2. Huang YL, Chen DR, Jiang YR, Kuo SJ, Wu HK, Moon WK: Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound. Ultrasound Obstet Gynecol; 2008 Sep;32(4):565-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound.
  • OBJECTIVES: To develop and evaluate a computer-aided diagnosis (CAD) system with automatic contouring and morphological analysis to aid in the classification of breast tumors using ultrasound.
  • METHODS: We evaluated 118 breast lesions (34 malignant and 84 benign tumors).
  • Each tumor contour was automatically extracted from the digitized ultrasound image.
  • A support vector machine (SVM) classifier utilized the selected principal vectors to identify the breast tumor as benign or malignant.
  • The classification ability for breast tumors using morphological information was good.
  • CONCLUSIONS: This system differentiates benign from malignant breast tumors well and therefore provides a clinically useful second opinion.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Diagnosis, Computer-Assisted / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Principal Component Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383556.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


3. Huang YL, Kuo SJ, Chang CS, Liu YK, Moon WK, Chen DR: Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems. Ultrasound Obstet Gynecol; 2005 Oct;26(5):558-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems.
  • OBJECTIVES: We present a computer-aided diagnostic (CAD) system with textural features and image retrieval strategies for classifying benign and malignant breast tumors on various ultrasonic systems.
  • This study evaluated a series of pathologically proven breast tumors using various ultrasonic systems.
  • METHODS: Altogether, 600 ultrasound images of solid breast nodules comprising 230 malignant and 370 benign tumors were investigated.
  • The suspicious tumor area in the ultrasound image was manually chosen as the region-of-interest (ROI) subimage.
  • Textural features extracted from the ROI subimage are supported in classifying the breast tumor as benign or malignant.
  • In practice, high-dimensional vectors are unsatisfactory at differentiating breast tumors.
  • The image retrieval techniques were employed to differentiate breast tumors, according to the similarities of the principal vectors.
  • The query ROI subimages were identified as malignant or benign tumors according to characteristics of retrieved images from the ultrasound image database.
  • CONCLUSION: The CAD system identified solid breast nodules with comparatively high accuracy in the different ultrasound systems investigated.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Area Under Curve. Breast Diseases / classification. Breast Diseases / ultrasonography. Databases, Factual. Female. Humans. Principal Component Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 ISUOG.
  • (PMID = 16086435.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.
  • The tumor cells were crowding, lack of an uniform morphology and polarity with intact myoepithelial cells around the ducts.
  • CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.
  • A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


5. Navas Cañete A, Olcoz Monreal FJ, García Laborda E, Pérez Aznar JM: [Pseudoangiomatous stromal hyperplasia: magnetic resonance findings in two cases]. Radiologia; 2007 Jul-Aug;49(4):275-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hiperplasia pseudoangiomatosa estromal: hallazgos en resonancia magnética de dos casos.
  • Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast tumor of uncertain etiology, although marked hormonal influence clearly plays a role in this disease.
  • The differential diagnosis is important because this is an uncommon lesion that can simulate malignant lesions both at clinical and radiological examination, and even the histological results can be confusing.
  • [MeSH-major] Breast / pathology. Breast Diseases / diagnosis. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594891.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • It is necessary to excise the tumour with sufficient margins to prevent local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [9413066.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):151-3 [11458280.001]
  • [Cites] Surg Today. 2002;32(8):716-9 [12181723.001]
  • [Cites] Arch Gynecol Obstet. 2003 Feb;267(4):233-5 [12592426.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):494-6 [14616945.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):783-6 [14526679.001]
  • (PMID = 23133273.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451846
  • [Keywords] NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
  •  go-up   go-down


7. Devi PM, Singh LR, Gatphoh ED: Fibroadenoma with squamous metaplasia. Singapore Med J; 2007 Jul;48(7):682-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenoma is the most common benign breast tumour in adolescent and young women.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Fibroadenoma / pathology
  • [MeSH-minor] Adult. Female. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / pathology. Humans. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609833.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


8. Ying MG, Chen Q, Ye YB, Chen HJ, Chen X, Zheng HY, Wu F: [Application of serum proteomic mass spectrum analysis in breast cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):698-702
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum proteomic mass spectrum analysis in breast cancer].
  • OBJECTIVE: To analyze the characteristics of serum proteins mass spectra in healthy controls, benign breast tumors, and CA15-3 negative or CA15-3 positive breast cancer patients by surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS).
  • METHODS: Tissue samples of 113 cases of breast cancer (93 case of CA15-3 negative, 20 case of CA15-3 positive), 103 cases of benign breast tumor and 92 cases of healthy controls were examined and analyzed by SELDI and protein chip (CM10) techniques.
  • RESULTS: Twelve significantly different protein peaks were found in serum samples between breast cancer patients and healthy controls.
  • Eleven significantly different peaks were found between benign breast tumor patients and healthy controls.
  • By combined analysis of those three different protein mass spectra, the peak 15 952 was found to be significantly different between breast cancer group and healthy controls, and the peak 7985 was significantly different among breast cancer group, benign breast tumor group and health controls.
  • The blind test with the differential proteins for the serum samples of 93 cases of CA15-3 negative breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 80.6% and specificity was 91.7%.
  • The blind test in 20 cases of CA15-3 positive breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 75.0% and specificity was 91.7%.
  • Four significantly different protein peaks were found between the benign breast tumor patients and CA15-3 negative breast cancer patients.
  • CONCLUSION: Significantly different protein peaks can be screened out in breast cancer, benign breast tumor patients and healthy controls by SELDI-TOF-MS analysis.
  • [MeSH-major] Blood Proteins / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Proteomics / methods
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Female. Humans. Middle Aged. Mucin-1 / metabolism. Protein Array Analysis. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122387.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Mucin-1
  •  go-up   go-down


9. Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B: Thyroid function in breast cancer patients. Anticancer Res; 2010 May;30(5):1713-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid function in breast cancer patients.
  • BACKGROUND: Recent studies indicate a possible relationship between hypothyroidism and breast cancer in vivo.
  • In addition, oestrogen-like effects of thyroid hormones on breast cancer cell growth are seen in vitro.
  • Therefore, this study evaluated thyroid function in breast cancer patients, women with benign breast tumour and healthy controls.
  • PATIENTS AND METHODS: Breast cancer patients (n=65), women with carcinoma in situ (n=13) or benign breast tumour (n=27), and healthy controls (n=38) were included in the study.
  • RESULTS: fT3 and fT4 levels were highest in breast cancer patients, and differed significantly from controls (fT3 and fT4: p<0.001) as well as from patients with benign breast tumour (fT3: p=0.021; fT4: p=0.017).
  • With regard to TRAK antibodies, breast cancer patients showed the highest levels differing significantly from women with benign breast tumours (p=0.048).
  • CONCLUSION: Significant differences in fT3/fT4 as well as TRAK levels were observed among breast cancer patients, women with benign breast tumours and healthy controls.
  • [MeSH-major] Breast Neoplasms / physiopathology. Thyroid Gland / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592366.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogens; 0 / Thyroid Hormones
  •  go-up   go-down


10. Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, Friese K, Toth B: CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res; 2010 May;30(5):1707-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients.
  • BACKGROUND: This is the first prospective case-control study that evaluates the expression of tumour-specific antigens on circulating microparticles (MP) in breast cancer patients and in women with benign breast tumour.
  • MATERIALS AND METHODS: MP were determined by flow cytometry in patients with breast cancer (n=34; T1 (n=19) and T2 (n=15)) and women with benign breast tumour (n=19).
  • RESULTS: Patients with lymph node metastases (N1, n=9) showed significantly higher numbers of annexin V(+) MP (p=0.042), CD66(+) MP (p=0.045), BCRP1(+) MP (breast cancer resistance protein) (p=0.025) and Hsp27(+) MP (p=0.034) than controls.
  • CONCLUSION: Significant differences are present between breast cancer patients with lymph node metastases and controls concerning annexin V-, CD66-, BCRP1- and Hsp27-positive MP.
  • To specify the role of these MP subpopulations in breast cancer progression, further studies enrolling larger patient groups are part of ongoing research.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Breast Neoplasms / metabolism. Carcinoembryonic Antigen / metabolism. Cell-Derived Microparticles. HSP27 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592365.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Annexin A5; 0 / Carcinoembryonic Antigen; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


11. Huang W, Li X, Morris EA, Tudorica LA, Seshan VE, Rooney WD, Tagge I, Wang Y, Xu J, Springer CS: The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci U S A; 2008 Nov 18;105(46):17943-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo.
  • In analyses of routine DCE-MRI data from 22 patients with suspicious breast lesions initially ruled positive by institutional screening protocols, the SM K(trans) values for benign and malignant lesions exhibit considerable overlap.
  • A form of the shutter-speed model (SSM), which allows for finite exchange kinetics, agrees with the SM K(trans) value for each of the 15 benign lesions.
  • However, it reveals that the SM underestimates K(trans) for each of the seven malignant tumors in this population.
  • The fact that this phenomenon is unique to malignant tumors allows their complete discrimination from the benign lesions, as validated by comparison with gold-standard pathology analyses of subsequent biopsy tissue samples.
  • Likewise, the SM overestimates k(ep), particularly for the benign tumors.
  • Thus, incorporation of the SSM into the screening protocols would have precluded all 68% of the biopsy/pathology procedures that yielded benign findings.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2004 Nov;52(5):1110-7 [15508148.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):724-9 [15723402.001]
  • [Cites] NMR Biomed. 2005 May;18(3):173-85 [15578708.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5464-73 [16027440.001]
  • [Cites] Magn Reson Med. 2005 Dec;54(6):1351-9 [16247739.001]
  • [Cites] Breast. 2006 Feb;15(1):137-40 [16005227.001]
  • [Cites] Cancer. 2006 May 15;106(10):2104-12 [16604564.001]
  • [Cites] NMR Biomed. 2006 Oct;19(6):681-9 [16986117.001]
  • [Cites] Eur Radiol. 2006 Dec;16(12):2619-21 [17061066.001]
  • [Cites] Magn Reson Med. 2007 Jan;57(1):220-5 [17152087.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):467-72 [17337650.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [17392385.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1295-303 [17392300.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Cancer Invest. 2007 Oct;25(7):518-26 [18027149.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):166-75 [17768665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17937-42 [19008355.001]
  • [Cites] NMR Biomed. 2009 Feb;22(2):148-57 [18727151.001]
  • [Cites] N Engl J Med. 2007 Apr 5;356(14):1399-409 [17409321.001]
  • [Cites] Magn Reson Med. 2000 Oct;44(4):563-74 [11025512.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1110-20 [12111957.001]
  • [Cites] Magn Reson Med. 2003 Sep;50(3):493-9 [12939756.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1151-69 [14648563.001]
  • [Cites] Magn Reson Med. 2004 Aug;52(2):248-57 [15282806.001]
  • [Cites] Radiology. 2004 Aug;232(2):585-91 [15205478.001]
  • [Cites] J Magn Reson B. 1994 Oct;105(2):99-112 [7952937.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] Radiology. 1996 Sep;200(3):639-49 [8756909.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):102-10 [9039599.001]
  • [Cites] Nat Med. 1997 Jul;3(7):780-2 [9212107.001]
  • [Cites] Radiology. 1998 Nov;209(2):499-509 [9807580.001]
  • [Cites] Magn Reson Med. 1999 Sep;42(3):467-78 [10467291.001]
  • [Cites] Radiology. 2005 Jan;234(1):79-85 [15618376.001]
  • (PMID = 19004780.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB-00422; United States / NCI NIH HHS / CA / R01 CA120861; United States / NIBIB NIH HHS / EB / R01 EB000422; United States / NINDS NIH HHS / NS / R01 NS-40801; United States / NINDS NIH HHS / NS / R01 NS040801; United States / NCI NIH HHS / CA / R01 CA-120861
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


12. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer; 2009;8:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
  • METHODS: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
  • RESULTS: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022).
  • The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034).
  • Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
  • CONCLUSION: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Cell Nucleus / genetics. DNA, Mitochondrial / blood
  • [MeSH-minor] Case-Control Studies. Cell-Free System. Cohort Studies. Diagnosis, Differential. Female. Health. Humans. Lymph Nodes / pathology. Neoplasm Metastasis. ROC Curve. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):905-8 [16900126.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:269 [17116247.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):157-63 [17280876.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Acta Paediatr. 2007 May;96(5):644-7 [17376185.001]
  • [Cites] Int J Biol Markers. 2007 Apr-Jun;22(2):95-9 [17549664.001]
  • [Cites] Arch Gynecol Obstet. 2007 Oct;276(4):327-31 [17431649.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • [Cites] Clin Chem Lab Med. 2008;46(3):311-7 [18254709.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):921-5 [18507037.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):699-703 [18549658.001]
  • [Cites] Int J Biol Markers. 2008 Apr-Jun;23(2):69-73 [18629778.001]
  • [Cites] DNA Cell Biol. 2008 Aug;27(8):415-21 [18694299.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • [Cites] Ann N Y Acad Sci. 2008 Aug;1137:175-9 [18837944.001]
  • [Cites] Cytokine. 2008 Oct;44(1):65-9 [18691902.001]
  • [Cites] Expert Rev Neurother. 2008 Dec;8(12):1841-52 [19086880.001]
  • [Cites] Neuroimage. 2009 Jun;46(2):394-410 [19236926.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1903-6 [11106320.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):310-1 [11214156.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 10;131(5-6):70-4 [11383228.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:138-40 [11708467.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Feb;48(2):187-92 [7540567.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Prenat Diagn. 2006 Apr;26(4):362-8 [16566058.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • (PMID = 19922604.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2780981
  •  go-up   go-down


13. Yao C, Wang SM, Xie D, Wu HX, Chen DY, Lin Y: [The relationship between expression of interleukin-8 and prognosis of breast cancer]. Zhonghua Wai Ke Za Zhi; 2006 Jul 1;44(13):900-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between expression of interleukin-8 and prognosis of breast cancer].
  • OBJECTIVE: To investigate the expression of interleukin-8 (IL-8) and its prognostic significance in breast cancer.
  • METHODS: Expression of IL-8 in 113 breast cancers, 19 breast benign tumors and 20 breast normal tissues was examined by tissue microarray using immunohistochemistry, and the association of IL-8 expression with patient's clinico-pathological characteristics and prognosis was further analyzed.
  • RESULTS: The positive rate of IL-8 expression in breast cancer was 27.4%, which was significantly higher than that in benign tumor and normal tissue of breast (P = 0.002).
  • CONCLUSIONS: IL-8 might be a poor prognostic factor for human breast cancer, and also might be a novel molecular marker to predicate the occurrence and progression of breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Interleukin-8 / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067482.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


14. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Concentration of cirDNA and methylation of RARbeta2, RASSF1A and HIC-1 gene promoters were investigated in cell-free and cell-surface-bound fractions from healthy donors, patients with breast cancer, and patients with breast fibroadenoma.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


15. Levine PH, Cangiarella J: Cytomorphology of benign breast disease. Clin Lab Med; 2005 Dec;25(4):689-712, vi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of benign breast disease.
  • Fine needle aspiration biopsy is a widely used technique for the initial diagnosis of mammary lesions.
  • The majority of patients undergoing fine needle aspiration biopsy of a breast lesion will have a benign disease of the breast.
  • This article provides a review of the cytomorphologic features in a variety of benign breast lesions,and discusses the commonly encountered differential diagnoses on aspiration biopsy.
  • Topics discussed include inflammatory and reactive conditions, treatment-induced changes, pregnancy-related changes, benign proliferative lesions, and benign neoplasms of the breast.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Breast Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Male. Pregnancy

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308087.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


16. Tokés AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res; 2005;7(2):R296-305
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.
  • INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions.
  • METHODS: Altogether, 56 sections from 52 surgically resected breast specimens were analyzed for CLDN1, CLDN3 and CLDN4 expression by immunohistochemistry. mRNA was also analyzed using real-time PCR in 17 of the 52 cases.
  • CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours).
  • However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia.
  • CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene.
  • CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue.
  • CONCLUSIONS: The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis.
  • [MeSH-major] Breast Diseases / genetics. Breast Neoplasms / genetics. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Claudin-1. Claudin-3. Claudin-4. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Tight Junctions

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cell Biol. 1999 Dec;78(12):849-55 [10669103.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48350-5 [11602598.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] J Cell Biol. 2002 Mar 18;156(6):1099-111 [11889141.001]
  • [Cites] J Cell Physiol. 2002 Apr;191(1):60-8 [11920682.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]
  • [Cites] Prog Biophys Mol Biol. 2003 Jan;81(1):1-44 [12475568.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Int J Mol Med. 2003 Jun;11(6):683-9 [12736707.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Jul;29(1):62-70 [12600828.001]
  • [Cites] Arch Androl. 2003 Jul-Aug;49(4):271-9 [12851029.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Sci. 1979 Feb;35:393-402 [422677.001]
  • [Cites] FEBS Lett. 1987 Sep 14;221(2):359-64 [3114004.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Cell Physiol. 1992 Jul;152(1):35-47 [1618921.001]
  • [Cites] J Cell Biol. 1998 Apr 20;141(2):397-408 [9548718.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1539-50 [9647647.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):391-401 [9786950.001]
  • [Cites] Gene. 1999 Jan 21;226(2):285-95 [9931503.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):268-73 [10370242.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1425-31 [10426787.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1035-8 [10508613.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):195-204 [10508866.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Hum Genet. 2000 Sep;107(3):249-56 [11071387.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):854-63 [11159859.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1319-27 [11375422.001]
  • [Cites] Clin Chem Lab Med. 2000 Feb;38(2):171-7 [10834406.001]
  • (PMID = 15743508.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1064136
  •  go-up   go-down


17. Jabłonowska E, Kołacinska A, Kuydowicz J, Przybyłowska K, Jabłonowski Z: Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients. Arch Med Sci; 2010 Dec;6(6):860-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients.
  • INTRODUCTION: Breast cancer and acquired immunodeficiency syndrome (AIDS) are key issues for modern medicine.
  • MATERIAL AND METHODS: Thirty-one women with benign breast tumours, 42 breast cancer patients and 40 HIV-infected females were enrolled in the study.
  • RESULTS: Serum IL-6 in patients with benign breast tumours was significantly lower than in females with breast cancer (p = 0.017) and HIV-infected women (p = 0.032).
  • We did not find statistically significant differences in serum IL-6 level between females with breast cancer and HIV-infected women (p = 0.749).
  • Comparing the distribution of genotypes and frequency of the IL-6 (-174) C/G polymorphism between the three study groups - breast cancer patients, patients with benign breast tumours, and HIV-infected patients - we did not find any statistically significant differences.
  • CONCLUSIONS: IL-6 can play an important role in pathogenesis of breast cancer and HIV infection and its level is higher than in the control group irrespective of distribution of genotypes and frequency of the IL-6 (-174) C/G polymorphism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22427758.001).
  • [ISSN] 1896-9151
  • [Journal-full-title] Archives of medical science : AMS
  • [ISO-abbreviation] Arch Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3302696
  • [Keywords] NOTNLM ; HIV / breast diseases / interleukin-6 / polymorphism
  •  go-up   go-down


18. Looi LM, Cheah PL, Ng MH, Yip CH, Mun KS, Rahman NA: Comparison of telomere length and telomerase activation between breast fibroadenoma and infiltrating ductal carcinoma in Malaysian women. Asian Pac J Cancer Prev; 2010;11(3):713-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of telomere length and telomerase activation between breast fibroadenoma and infiltrating ductal carcinoma in Malaysian women.
  • A study was initiated to explore possible differences in handling telomere attrition in the most common lignant and benign tumours of the breast in Malaysian women.
  • Infiltrating ductal carcinoma (IDC) and fibroadenoma (FA) represented the malignant and benign prototypes respectively.
  • 29 IDC, 28 FA and 22 benign non-lesional control (BNL) breast tissue samples were analysed for telomerase activation using a Telomerase PCR ELISA kit (Boehringer Mannheim).
  • The findings imply that telomere attrition and telomerase activation differ between malignant and benign tumours of the breast and may be important for targeted therapy.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / pathology. Telomerase / metabolism. Telomere / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Polymerase Chain Reaction. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039041.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


19. Kukreti S, Cerussi AE, Tanamai W, Hsiang D, Tromberg BJ, Gratton E: Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy. Radiology; 2010 Jan;254(1):277-84
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy.
  • PURPOSE: To develop a near-infrared spectroscopic method to identify breast cancer biomarkers and to retrospectively determine if benign and malignant breast lesions could be distinguished by using this method.
  • By using self-referencing differential spectroscopy (SRDS) analysis, the existence of specific spectroscopic signatures of breast lesions on images acquired by using diffuse optical spectroscopy imaging in the wavelength range (650-1000 nm) was established.
  • There were 17 patients with benign breast tumors and 22 patients with malignant breast tumors.
  • RESULTS: Discrimination analysis helped separate malignant from benign tumors.
  • A total of 40 lesions (22 malignant and 18 benign) were analyzed.
  • CONCLUSION: The SRDS method revealed localized tumor biomarkers specific to pathologic state.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):383-91 [10989610.001]
  • [Cites] Breast Cancer Res Treat. 2007 Sep;104(3):249-55 [17051424.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1016-22 [11308247.001]
  • [Cites] Magn Reson Med. 2001 Jun;45(6):994-1000 [11378876.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):45-54 [11678308.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):60-71 [11818013.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1197-203 [12189222.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1134-43 [14648561.001]
  • [Cites] Breast. 2003 Jun;12(3):179-82 [14659324.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):464-73 [15189083.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):541-52 [15189092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6468-73 [9177241.001]
  • [Cites] Radiology. 1998 Oct;209(1):269-75 [9769842.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):159-64 [10441019.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1737-46 [10470108.001]
  • [Cites] Radiology. 2004 Nov;233(2):424-31 [15516615.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2451-68 [15901948.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] J Lipid Res. 2005 Sep;46(9):1983-90 [15961785.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051503 [16292947.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):427-35 [16465174.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S302-5 [16507398.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):325-32 [16786567.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Expert Rev Med Devices. 2007 Jan;4(1):83-95 [17187474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):020509 [17477706.001]
  • [Cites] Radiology. 2001 Jan;218(1):261-6 [11152812.001]
  • (PMID = 20032159.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142989; United States / NCI NIH HHS / CA / U54 CA136400-01; None / None / / P41 RR001192-31; United States / NCI NIH HHS / CA / R01 CA142989-01; United States / NCRR NIH HHS / RR / P41 RR001192-31; United States / NIBIB NIH HHS / EB / R01 EB000559; United States / NCI NIH HHS / CA / U54 CA136400-02; United States / NCI NIH HHS / CA / U54 CA105480-05; United States / NCI NIH HHS / CA / U54 CA105480; United States / NCI NIH HHS / CA / U54 CA136400; United States / NCI NIH HHS / CA / R01 CA142989-02; United States / NCI NIH HHS / CA / P30-CA62203; United States / NCRR NIH HHS / RR / P41 RR003155; United States / NCRR NIH HHS / RR / P41 RR001192; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCRR NIH HHS / RR / P41-RR01192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2797652
  •  go-up   go-down


20. Yang W, Zhang S, Chen Y, Li W, Chen Y: Shape symmetry analysis of breast tumors on ultrasound images. Comput Biol Med; 2009 Mar;39(3):231-8
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shape symmetry analysis of breast tumors on ultrasound images.
  • Shape characteristics of malignant and benign breast tumors are significantly different.
  • In this paper, the reflective symmetry of breast tumor shapes on ultrasound images was investigated.
  • A new reflective symmetry measure (RSML) derived from multiscale local area integral invariant was proposed to quantify the shape symmetry of breast tumor, which could be computed directly from the binary mask image without the shape parameterization in terms of arc length.
  • The performance of several symmetry measures for differentiating malignant and benign breast tumors at varying scales was evaluated and compared by receiver operating characteristic (ROC) analysis.
  • RSML with Gaussian kernel at scale 0.04 (related to the maximal diameter) achieved the highest area under the ROC curve (0.85) on the image data of 168 tumors (104 benign and 64 malignant).
  • The experimental results showed that the reflective symmetry of breast tumor shape was capable of providing potential diagnostic information, which could be characterized quantitatively by RSML with the appropriate scale parameter.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Ultrasonography / methods. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178908.001).
  • [ISSN] 1879-0534
  • [Journal-full-title] Computers in biology and medicine
  • [ISO-abbreviation] Comput. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Nalini R, Wilma Delphine Silvia CR, Uthappa S: Utility of blood DNA levels in diagnosis of breast cancer. J Cancer Res Ther; 2008 Apr-Jun;4(2):57-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of blood DNA levels in diagnosis of breast cancer.
  • BACKGROUND: Prognostic factors, including both histopathological and biochemical variables, influence the choice of modality and the course of therapy in breast cancer.
  • AIM: To find out if any correlation exists between blood DNA level and tumor stage, size and grade.
  • The cases comprised 25 patients with histopathologically confirmed malignant breast cancer, while 27 patients with benign breast tumors served as the control group.
  • Pearson's test was performed to find out the correlation between blood DNA levels and the TNM stage, tumor size and grade.
  • RESULTS: It was observed that blood DNA levels showed statistically significant correlation with the TNM stage, tumor size and grade.
  • CONCLUSION: The blood DNA level can be utilized as a noninvasive marker to assess tumor aggressiveness.
  • Thus, it can be useful as a prognostic marker and as a marker of tumor burden.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. DNA, Neoplasm / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms / diagnosis. Neoplasms / surgery. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688119.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


22. Fujita T, Hayashi K, Katanoda K, Matsumura Y, Lee JS, Takagi H, Suzuki S, Mizunuma H, Aso T: Prevalence of diseases and statistical power of the Japan Nurses' Health Study. Ind Health; 2007 Oct;45(5):687-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For all diseases except ovarian cancer, the prevalence of a past diagnosis increased markedly with age, and incidence rates could be predicted based on the degree of increase in prevalence between two adjacent 5-yr age groups.
  • The predicted incidence rate for uterine myoma, hypercholesterolemia, and hypertension was > or =3.0 (per 1,000 women, per year), while the rate of thyroid disease, hepatitis, gallstone disease, and benign breast tumor was predicted to be > or =1.0.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057812.001).
  • [ISSN] 0019-8366
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


23. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


24. Ikeda S, Shibata T, Funakoshi N: Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast. Rinsho Byori; 2005 Jun;53(6):487-93
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast.
  • Telomerase activity is associated with immortality and is expressed in various malignant tumors.
  • In this study, the expression of TERT was investigated by immunocytochemistry to determine whether it is a useful marker for differential diagnosis in benign or malignant breast tumors.
  • We examined imprint smears prepared from 63 surgically resected breast lesions, and 27 cases of secretion or aspiration cytology smears had been routinely diagnosed.
  • In conclusion, the expression of TERT protein might be a useful marker for differential diagnosis in malignant and benign breast tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. DNA-Binding Proteins / analysis. Telomerase / analysis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. In Situ Hybridization. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rinsho Byori.2005 Aug;53(8):748
  • (PMID = 16026073.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


25. Preda A, Novikov V, Möglich M, Floyd E, Turetschek K, Shames DM, Roberts TP, Corot C, Carter WO, Brasch RC: Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol; 2005 Nov;15(11):2268-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
  • Carboxymethyldextran (CMD)-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a molecular weight of 52.1 kDa, designed to have intravascular residence for more than 1 h, was evaluated for its potential to characterize and differentiate the microvessels of malignant and benign breast tumors.
  • Precontrast single-slice inversion-recovery snapshot FLASH and dynamic contrast-enhanced MRI using an axial T1-weighted three-dimensional spoiled gradient recalled sequence was performed in 30 Sprague-Dawley rats with chemically induced breast tumors.
  • Endothelial transfer coefficient and fractional plasma volume of the breast tumors were estimated from MRI data acquired with CMD-A2-Gd-DOTA enhancement injected at a dose of 0.1 mmol Gd/kg body weight using a two-compartment bidirectional model of the tumor tissue.
  • The correlation between MRI microvessel characteristics and histopathological tumor grade was determined using the Scarff-Bloom-Richardson method.
  • Using CMD-A2-Gd-DOTA, no significant correlations were found between the MR-estimated endothelial transfer coefficient or plasma volumes with histological tumor grade.
  • Analysis of CMD-A2-Gd-DOTA-enhanced MR kinetic data failed to demonstrate feasibility for the differentiation of benign from malignant tumors or for image-based tumor grading.
  • [MeSH-major] Magnetic Resonance Imaging. Mammary Neoplasms, Experimental / blood supply. Mammary Neoplasms, Experimental / pathology. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1998;16(4):225-30 [9589031.001]
  • [Cites] Anticancer Res. 1991 Sep-Oct;11(5):1783-92 [1837443.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):170-7 [10441021.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):956-63 [11035346.001]
  • [Cites] Sci Am. 1994 Jul;271(1):58-65 [8066425.001]
  • [Cites] J Magn Reson Imaging. 2001 Sep;14(3):237-42 [11536400.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8 [2061479.001]
  • [Cites] Radiology. 2001 Feb;218(2):562-9 [11161179.001]
  • [Cites] Acta Radiol Suppl. 1997;412:91-9 [9240087.001]
  • [Cites] Invest Radiol. 1994 Jun;29 Suppl 2:S8-11 [7928277.001]
  • [Cites] Radiat Res. 1985 Mar;101(3):460-72 [3983362.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):117-31 [2255233.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Magn Reson Imaging. 1992;10(1):97-108 [1545688.001]
  • [Cites] Radiology. 1996 Mar;198(3):893-8 [8628889.001]
  • [Cites] Magn Reson Med. 1993 May;29(5):616-22 [8505897.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):448-55 [12722742.001]
  • [Cites] Invest Radiol. 1996 May;31(5):288-93 [8724128.001]
  • [Cites] Invest Radiol. 2000 Apr;35(4):213-8 [10764089.001]
  • [Cites] Eur Radiol. 2003 Feb;13(2):354-65 [12599002.001]
  • [Cites] Invest Radiol. 1991 Dec;26(12 ):1035-40 [1722486.001]
  • [Cites] AJR Am J Roentgenol. 1998 Oct;171(4):941-9 [9762973.001]
  • [Cites] Radiology. 1996 Mar;198(3):813-8 [8628876.001]
  • [Cites] J Magn Reson Imaging. 1999 Feb;9(2):177-86 [10077011.001]
  • [Cites] Magn Reson Med. 2001 May;45(5):880-6 [11323815.001]
  • [Cites] Magn Reson Med. 1995 Dec;34(6):845-52 [8598811.001]
  • [Cites] Eur Radiol. 2001;11(7):1276-84 [11471624.001]
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):882-8 [11382948.001]
  • [Cites] Radiology. 1999 Oct;213(1):265-72 [10540670.001]
  • [Cites] Magn Reson Med. 1990 Jan;13(1):77-89 [2319937.001]
  • [Cites] Anticancer Res. 1984 Jan-Apr;4(1-2):5-12 [6712176.001]
  • [Cites] J Magn Reson Imaging. 1999 Jun;9(6):777-85 [10373025.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):82-90 [9039597.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7022-32 [3191477.001]
  • [Cites] Magn Reson Med. 2000 Mar;43(3):403-9 [10725883.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1299-305 [3040213.001]
  • (PMID = 16012822.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / carboxymethyl-dextran-A2-gadolinium-DOTA
  •  go-up   go-down


26. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A; 2008 Sep 23;105(38):14533-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
  • Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
  • Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
  • Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(6):483-8 [3321867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5 [7537382.001]
  • [Cites] Mol Endocrinol. 1996 Jan;10(1):45-56 [8838144.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29707-14 [8939904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):841-4 [17299388.001]
  • [Cites] BMC Med Genet. 2007;8:72 [18053149.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Endocrine. 2003 Feb-Mar;20(1-2):177-90 [12668884.001]
  • [Cites] Recent Prog Horm Res. 2003;58:297-323 [12795425.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10024-34 [10187780.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):555-62 [16278261.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9 [16434456.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):271-85 [16899561.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):718-28 [14613905.001]
  • (PMID = 18779591.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • [Other-IDs] NLM/ PMC2567233
  • [Investigator] Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
  •  go-up   go-down


27. Buch A, Rout P, Makhija P: Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump. Indian J Pathol Microbiol; 2006 Apr;49(2):259-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
  • An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.
  • Both these tumors have tendencies to recur and have malignant potential.
  • This patient also presented with a recurrent breast neoplasm.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933731.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


28. Yegingil H, Shih WY, Shih WH: Probing model tumor interfacial properties using piezoelectric cantilevers. Rev Sci Instrum; 2010 Sep;81(9):095104
Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing model tumor interfacial properties using piezoelectric cantilevers.
  • Invasive malignant breast cancers are typically branchy and benign breast tumors are typically smooth.
  • It is of interest to characterize tumor branchiness (roughness) to differentiate invasive malignant breast cancer from noninvasive ones.
  • In this study, we examined the shear modulus (G) to elastic modulus (E) ratio, G/E, as a quantity to describe model tumor interfacial roughness using a piezoelectric cantilever capable of measuring both tissue elastic modulus and tissue shear modulus.
  • We constructed model tissues with tumors by embedding one-dimensional (1D) corrugated inclusions and three-dimensional (3D) spiky-ball inclusions made of modeling clay in gelatin.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrasonics. 2000 Mar;38(1-8):400-4 [10829696.001]
  • [Cites] Arch Surg. 2001 Feb;136(2):204-8 [11177142.001]
  • [Cites] J Digit Imaging. 2002;15 Suppl 1:224-7 [12105735.001]
  • [Cites] Ultrasound Med Biol. 2003 Jun;29(6):813-23 [12837497.001]
  • [Cites] Annu Rev Biomed Eng. 2003;5:57-78 [12704084.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jan;23(1):111-21 [14719692.001]
  • [Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]
  • [Cites] Phys Med Biol. 2006 Jan 21;51(2):425-41 [16394348.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):215-28 [15798297.001]
  • [Cites] Phys Med Biol. 2007 Mar 21;52(6):1565-76 [17327649.001]
  • [Cites] Med Eng Phys. 2008 Oct;30(8):1013-9 [18495518.001]
  • [Cites] Rev Sci Instrum. 2007 Nov;78(11):115101 [18052498.001]
  • [Cites] Med Image Anal. 2007 Aug;11(4):361-73 [17509927.001]
  • (PMID = 20887005.001).
  • [ISSN] 1089-7623
  • [Journal-full-title] The Review of scientific instruments
  • [ISO-abbreviation] Rev Sci Instrum
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000720; United States / NIBIB NIH HHS / EB / 1 R01 EB000720
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 12626-81-2 / lead titanate zirconate; 1302-87-0 / clay; 2P299V784P / Lead; C6V6S92N3C / Zirconium; D1JT611TNE / Titanium
  • [Other-IDs] NLM/ PMC2955722
  •  go-up   go-down


29. Yom CK, Moon BI, Choe KJ, Choi HY, Park YL: Long-term results after excision of breast mass using a vacuum-assisted biopsy device. ANZ J Surg; 2009 Nov;79(11):794-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after excision of breast mass using a vacuum-assisted biopsy device.
  • BACKGROUND: The excision of breast lesions using an ultrasound-guided vacuum-assisted biopsy device (VABD) is a widely used technique for the diagnosis and treatment of breast disease, but the results of long-term follow-up after VABD excision of benign breast tumours have not been reported.
  • The purpose of this study was to evaluate the results of long-term follow-up after complete excision of benign breast tumours using an ultrasound-guided VABD.
  • Between January 2001 and December 2004, patients who had undergone VABD excision of benign breast tumours and been followed up by clinical examination and ultrasonography for 2 years or more were included.
  • All lesions were histologically benign.
  • Finally, the benign breast tumours were completely excised without residual masses in 93.5% of the participant patients.
  • CONCLUSION: Ultrasound-guided VABD excision is a minimally invasive technique for the complete removal of benign breast tumours.
  • [MeSH-major] Breast Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle / instrumentation. Biopsy, Needle / methods. Female. Fibroadenoma / surgery. Fibrocystic Breast Disease / surgery. Humans. Middle Aged. Retrospective Studies. Surgery, Computer-Assisted. Treatment Outcome. Ultrasonography, Interventional / methods. Ultrasonography, Mammary. Vacuum. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078528.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


30. Mizukami Y, Takayama T, Takemura A, Ichikawa K, Onoguchi M, Miyati T, Taniya T: Pleomorphic adenoma of the breast. Radiat Med; 2008 Aug;26(7):442-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the breast.
  • Pleomorphic adenoma is a very rare benign tumor of the breast.
  • Recently, we encountered a case of pleomorphic adenoma of the breast and thus present here the mammographic and ultrasonographic findings with the pathology of this rare breast tumor.
  • The patient was a 76-year-old Japanese woman with a right breast mass.
  • Awareness of this type of tumor will help in correct diagnosis, in spite of the rarity of this disease.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Breast Neoplasms / diagnosis
  • [MeSH-minor] Aged. Breast / surgery. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mammography / methods. Rare Diseases. Treatment Outcome. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770004.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. El Tarhouny S, Seefeld M, Fan AX, Hahn S, Holzgreve W, Zhong XY: Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine; 2008 Oct;44(1):65-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
  • We wanted to find out whether VEGF, VEGFR1 or cfDNA is a biomarker for breast cancer.
  • METHODS: In this study, we used enzyme-linked immunosorbent assay (ELISA) to examine the levels of serum VEGF and VEGFR1 in 23 patients with benign tumors, 19 patients with breast cancer and 32 age-matched healthy females.
  • RESULTS: In terms of serum levels of either VEGF or its soluble receptors VEGFR1, we found no significant difference between healthy individuals and women with benign breast tumors and breast cancer.
  • However, there was a significant increase in circulating cell-free DNA in women with both benign and malignant breast tumors when compared with the corresponding healthy control group.
  • CONCLUSIONS: We can conclude that quantitative analysis of circulating cell-free DNA in serum may provide molecular biological understanding of breast tumors in women.
  • [MeSH-major] Breast Neoplasms / blood. DNA / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor Receptor-1 / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691902.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9007-49-2 / DNA; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


32. Caldefie-Chézet F, Damez M, de Latour M, Konska G, Mishellani F, Fusillier C, Guerry M, Penault-Llorca F, Guillot J, Vasson MP: Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun; 2005 Sep 2;334(3):737-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma.
  • It was also shown to stimulate the proliferation of breast cancer cell lines.
  • In this study, we conducted an immunohistochemical analysis of leptin expression in normal tissue and benign and malignant ductal breast cell, representing the different states of the invasion process.
  • We determined for the first time that leptin is expressed both by ductal breast tumors and by benign lesions as atypical hyperplasia.
  • This suggests that leptin may be taken up or synthesized by all modified ductal breast cells, and may prove a proliferative factor.
  • Moreover, leptin is unexpressed by normal tissue in the healthy breast but is exhibited by the normal tissue in near vicinity of the malignant ductal breast lesions.
  • We also postulated that leptin may be a prognostic or diagnostic factor for ductal breast cancer.
  • [MeSH-major] Breast Neoplasms / physiopathology. Carcinoma, Ductal, Breast / physiopathology. Leptin / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / metabolism. Carcinoma in Situ / physiopathology. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009333.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


33. Braendle W, Kuhl H, Mueck A, Birkhäuser M, Thaler C, Kiesel L, Neulen J: [Does hormonal contraception increase the risk for tumors?]. Ther Umsch; 2009 Feb;66(2):129-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does hormonal contraception increase the risk for tumors?].
  • A non-contraceptive benefit of oral hormonal contraceptives (OC) is a diminished risk for certain benign as well as malignant tumours, such as benign breast tumours, uterine fibroids and ovarian cysts.
  • Modern data do not suggest an increased risk for breast carcinoma in OC users.
  • [MeSH-major] Contraceptives, Oral, Hormonal / adverse effects. Neoplasms / chemically induced
  • [MeSH-minor] Adult. Age Factors. Case-Control Studies. Female. Genital Neoplasms, Female / chemically induced. Genital Neoplasms, Female / genetics. Humans. Long-Term Care. Middle Aged. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180433.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal
  • [Number-of-references] 47
  •  go-up   go-down


34. Ye YB, Zhou ZF, Chen Q, Li JY, Chen X, Huang WW: [The roles of soluble MICA in immune escape of breast tumor]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep;24(9):904-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The roles of soluble MICA in immune escape of breast tumor].
  • AIM: To determine the expression of soluble MICA (sMICA) in serum of patients with breast tumor, and explore the roles of sMICA in immune escape.
  • The cytotoxicity of NK cells to breast cancer cells was observed with MTT assay.
  • RESULTS: sMICA was not detected in the serum of healthy person, but(76.8+/-22.3) ng/L in breast benign tumor patients and (205.4+/-71.3) ng/L in breast malignant tumor patients.
  • There was positive correlation between sMICA levels and breast cancer stage.
  • IL-15 up-regulated the expression of NKG2D on NK cells and increased NK cells cytotoxicity to breast cancer cells.
  • CONCLUSION: sMICA level is positive correlated with breast cancer TNM stage. sMICA reduced the expression of NKG2D, impaired NK-mediated immune surveillance and led to immune escape of breast tumor.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / immunology. Histocompatibility Antigens Class I / blood
  • [MeSH-minor] Cells, Cultured. Cytotoxicity, Immunologic. Female. Humans. Killer Cells, Natural / immunology. Neoplasm Staging. Solubility

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782524.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / MHC class I-related chain A
  •  go-up   go-down


35. Chang RF, Huang SF, Moon WK, Lee YH, Chen DR: Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification. Radiology; 2007 Apr;243(1):56-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification.
  • PURPOSE: To retrospectively evaluate the accuracy of neural network analysis of tumor vascular features at three-dimensional (3D) power Doppler ultrasonography (US) for classification of breast tumors as benign or malignant, with histologic findings as the reference standard.
  • Three-dimensional power Doppler US images of 221 solid breast masses (110 benign, 111 malignant) were obtained in 221 women (mean age, 46 years; range, 25-71 years).
  • A neural network was used to classify tumors by using these features.
  • RESULTS: Mean values of vessel-to-volume ratio, number of vascular trees, total vessel length, longest path length, number of bifurcations, and vessel diameter were 0.0089 +/- 0.0073 (standard deviation), 26.41 +/- 14.73, 23.02 cm +/- 19.53, 8.44 cm +/- 10.38, 36.31 +/- 37.06, and 0.088 cm +/- 0.021 in malignant tumors, respectively, and 0.0028 +/- 0.0021, 9.69 +/- 6.75, 5.17 cm +/- 4.78, 1.68 cm +/- 1.79, 6.05 +/- 7.55, and 0.064 cm +/- 0.028 in benign tumors, respectively (P < .001 for all six features).
  • CONCLUSION: Three-dimensional power Doppler US images and neural network analysis of features can aid in classification of breast tumors as benign or malignant.
  • [MeSH-major] Breast / blood supply. Breast Neoplasms / ultrasonography. Imaging, Three-Dimensional / methods. Neural Networks (Computer)

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312276.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Harsløf SS, Andersen LM, Hoyer U, Christiansen JJ: [Breast cancer metastasis to the colon]. Ugeskr Laeger; 2010 Aug 23;172(34):2309-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cancer metastasis to the colon].
  • She was diagnosed with metastases of a carcinoma to the colon; the immunohistochemical profile made lobular breast cancer the most likely primary tumour.
  • But despite thorough examination, such tumour was never found.
  • Twenty-two years earlier, the patient underwent surgery for a benign breast tumour.
  • The benign diagnosis was confirmed in new slides from the then removed tissue.
  • Metastases from breast cancer to the colon are rare, and a primary tumour is usually found.
  • In this case report, however, no primary tumour was found.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonic Neoplasms / secondary. Female. Humans. Neoplasms, Unknown Primary / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727298.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


37. Elusoji SO, Famodu AA, Aigbe A, Osime C, Iribhogbe PE, Oludiran O, Egwakhide E, Elusoji C, Oluedo A: Haemorheological changes in African breast cancer patients. Afr J Reprod Health; 2008 Apr;12(1):84-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haemorheological changes in African breast cancer patients.
  • Packed cell volume (PCV), heamoglobin (Hb), relative plasma viscosity (RPV) and plasma Fibrinogen concentration (PFC) were measured in 50 healthy control women, 50 age-matched women with breast cancer, and 10 women with histophathologically proven benign breast tumour.
  • There were significant differences between the controls and breast cancer patients in all the parameters measured (p < 0.05).
  • Since increased fibrinogen may give rise to increase fibrin formation which has been asserted as an independent cardiovascular risk factor for thromb-oembolic complications, African patients with breast cancer may well be predisposed to thrombotic complications during illness.
  • The theological assessment may offer valuable benefit for the management and early diagnosis of breast cancer in African women.
  • [MeSH-major] Blood Viscosity. Breast Neoplasms / blood. Fibrinogen / analysis. Hematocrit. Hemorheology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20695159.001).
  • [ISSN] 1118-4841
  • [Journal-full-title] African journal of reproductive health
  • [ISO-abbreviation] Afr J Reprod Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 9001-32-5 / Fibrinogen
  •  go-up   go-down


38. Cashell AW: Apocrine adenoma of the breast. W V Med J; 2008 Mar-Apr;104(2):16-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenoma of the breast.
  • A case of apocrine adenoma, a rare benign tumor of the breast is reported.
  • A left breast nodule from a 47-year-old female was found by mammography and excised.
  • The tumor was well circumscribed and composed of tightly packed tubules lined by cells with apocrine features.
  • Apocrine adenomas have been reported arising in a variety of sites including the breast, (1-5) perianal region, (6,7) eyelid, (8) and axilla. (9) Their appearance has similarities to the apocrine metaplasia commonly seen in fibrocystic change of the breast but they are well-circumscribed tumors with closely packed tubular and papillary structures.
  • They are not distinctive by mammography or physical examination and should be managed as any other breast mass.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Breast Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491794.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Liu C, Yan X, Zhang X, Yang W, Peng W, Shi D, Zhu P, Huang W, Yuan Q: Evaluation of x-ray diffraction enhanced imaging in the diagnosis of breast cancer. Phys Med Biol; 2007 Jan 21;52(2):419-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of x-ray diffraction enhanced imaging in the diagnosis of breast cancer.
  • The significance of the x-ray diffraction enhanced imaging (DEI) technique in the diagnosis of breast cancer and its feasibility in clinical medical imaging are evaluated.
  • Different massive specimens including normal breast tissues, benign breast tumour tissues and malignant breast tumour tissues are imaged with the DEI method.
  • The differences in DEI images and their rocking curves are evaluated for early diagnosis of breast cancers.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / radiography. Mammography / methods
  • [MeSH-minor] Absorption. Algorithms. Breast / pathology. Female. Humans. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Radiographic Image Enhancement. Radiographic Image Interpretation, Computer-Assisted. Scattering, Radiation. X-Ray Diffraction. X-Rays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202624.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Chen YW, Chuang YW, Lai YC, Hsieh JS, Liu GC, Hou MF: Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor? Ann Nucl Med; 2006 Jan;20(1):45-50
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor?
  • OBJECTIVE: In this article, we will discuss the achievement of early dynamic lymphoscintigraphic protocol and compare detection of sentinel node between benign and malignant breast tumors, and whether pathologic factor is related or not.
  • The average age of patients was 47.6 +/- 9.8 years and all of them were clinically suspected of having breast cancer.
  • The average tumor was 2.1 +/- 1.1 cm in size.
  • All patients underwent surgery sixteen to twenty hours later and had a final pathological diagnosis.
  • From the summation image of dynamic study, identified axillary sentinel nodal activity was found as 80% in the group of benign breast tumor, but only 48% in the group of malignant breast tumor.
  • However, this short period of protocol is not always achievable to detect sentinel node, especially in the group with breast malignant lesions.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Breast Neoplasms / secondary. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Sentinel Lymph Node Biopsy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485574.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


41. Thitaikumar A, Mobbs LM, Kraemer-Chant CM, Garra BS, Ophir J: Breast tumor classification using axial shear strain elastography: a feasibility study. Phys Med Biol; 2008 Sep 7;53(17):4809-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor classification using axial shear strain elastography: a feasibility study.
  • In this paper, we report a feasibility study on the utility of the axial-shear strain elastograms in the classification of in vivo breast tumor as being benign or malignant.
  • The study was performed using data sets obtained from 15 benign and 15 malignant cases that were biopsy proven.
  • The observers also outlined the tumor area on the corresponding sonogram, which was used to normalize the area of the axial-shear strain region.
  • First, the result indicates that the observers consistently ( approximately 82% of the cases) noticed the characteristic pattern of the axial-shear strain distribution data as predicted in the previous simulation studies, i.e. alternating regions of positive and negative axial-shear strain values around the tumor-background interface.
  • Second, the analysis of the result suggests that in approximately 57% of the cases in which the observers did not visualize tumor in the sonogram, the elastograms helped them to locate the tumor.
  • Feature values between 0.46 and 0.75 may result in an overlap between benign and malignant cases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Elasticity Imaging Techniques / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701768.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Seefeld M, El Tarhouny S, Fan AX, Hahn S, Holzgreve W, Zhong XY: Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors. Int J Biol Markers; 2008 Apr-Jun;23(2):69-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors.
  • OBJECTIVES: In order to assess the potential biomolecules for breast cancer, we analyzed in parallel the levels of cell-free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cell-free nucleosomes in serum samples from patients with benign and malignant breast tumors.
  • METHODS: Twenty-three patients with benign breast tumors, 27 patients with breast cancer, and 32 age-matched healthy women were recruited.
  • RESULTS: The levels of cell-free GAPDH were significantly higher in the serum samples of patients with benign and malignant breast tumors than in those of the control group (median 37,966 GE/mL, range 3,802-130,104 versus 11,770 GE/mL, range 2,198-73,522, p=0.035 and median 40,698 GE/mL, range 3,644-192,482 versus 11,770 GE/mL range 2,198-73,522, p=0.001).
  • There was, however, no significant difference between healthy individuals and women with benign breast tumors or breast cancer in terms of nucleosomes determined by ELISA.
  • CONCLUSION: Our data suggest that the cell-free serum GAPDH DNA assayed by quantitative PCR is a better biomarker than nucleosomes assayed by ELISA in patients with breast tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. DNA / blood. Enzyme-Linked Immunosorbent Assay / methods. Nucleosomes. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629778.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nucleosomes; 9007-49-2 / DNA; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


43. Min Y, Ren X, Vaught DB, Chen J, Donnelly E, Lynch CC, Lin PC: Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer. Cancer Res; 2010 Apr 1;70(7):2819-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.
  • Breast to bone metastasis is a common occurrence in the majority of patients with advanced breast cancer.
  • Understanding the underlying mechanisms of how metastatic tumor cells induce bone destruction is critically important.
  • We previously reported that Tie2, a receptor tyrosine kinase, is significantly increased in human breast cancer tissues compared with normal and benign breast tumors and regulates tumor angiogenesis.
  • In this study, we identify a new function of Tie2 in osteoclastogenesis and osteolytic bone invasion of breast cancer.
  • Consistently, neutralization of Tie2 activity in vivo significantly inhibited osteolytic bone invasion and tumor growth in a mammary tumor model, which correlated with a significant reduction of osteoclasts and tumor angiogenesis.
  • These findings identify Tie2 as a therapeutic target for controlling not only tumor angiogenesis but also osteolytic bone metastasis in breast cancer.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol In Vitro. 2001 Aug-Oct;15(4-5):455-61 [11566578.001]
  • [Cites] Ann N Y Acad Sci. 2007 Nov;1117:12-25 [18056034.001]
  • [Cites] Cell. 2004 Jul 23;118(2):149-61 [15260986.001]
  • [Cites] Nature. 1980 Feb 14;283(5748):669-70 [7354855.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):66-80 [1555533.001]
  • [Cites] Osteoporos Int. 1997;7(1):39-43 [9102061.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2072-8 [9329972.001]
  • [Cites] Br J Cancer. 1998;77(1):51-6 [9459145.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8829-34 [9671764.001]
  • [Cites] Stem Cells. 2005;23(1):134-43 [15625130.001]
  • [Cites] Arthritis Rheum. 2005 May;52(5):1585-94 [15880817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14016-21 [16172397.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4257-66 [16518413.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):816-23 [17289872.001]
  • [Cites] Bone. 2007 Apr;40(4):1032-40 [17251073.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2007 Jan;43(1):21-4 [17570030.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):1019-25 [17825261.001]
  • [Cites] Trends Immunol. 2007 Dec;28(12):519-24 [17981504.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • (PMID = 20233869.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108856; United States / NIAMS NIH HHS / AR / R01 AR053718-04; United States / NIAMS NIH HHS / AR / R01 AR053718; United States / NINDS NIH HHS / NS / NS45888; United States / NIAMS NIH HHS / AR / AR053718-04; United States / NCI NIH HHS / CA / R01 CA108856-05; United States / NINDS NIH HHS / NS / R01 NS045888-04; United States / NCI NIH HHS / CA / CA108856-05; United States / NINDS NIH HHS / NS / R01 NS045888; United States / NINDS NIH HHS / NS / NS045888-04; United States / NIAMS NIH HHS / AR / AR053718; United States / NCI NIH HHS / CA / CA108856
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Tek protein, mouse; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ NIHMS174219; NLM/ PMC2848896
  •  go-up   go-down


44. Eroğlu A, Sari A: Expression of c-kit proto-oncogene product in breast cancer tissues. Med Oncol; 2007;24(2):169-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit proto-oncogene product in breast cancer tissues.
  • BACKGROUND: The published results on expression of c-kit in benign and malignant breast tissues vary.
  • MATERIALS AND METHODS: The immunohistochemical expression of c-kit proto-oncogene product in 52 invasive breast cancer tissues and 16 benign breast tumor (fibroadenoma) tissues was studied using anti-c-kit proto-oncogene product antibody.
  • RESULTS: In breast cancer tissues, the mean IRS of c-kit proto-oncogene product expression was significantly increased compared to those of fibroadenoma (3.4 +/- 2 and 2.19 +/- 1.8, respectively,p = 0.035).
  • The mean IRS of c-kit expression was higher in the group comprising estrogen (ER) positive tumor than in the group of ER negative (4.1 +/- 2.1 and 2.7 +/- 1.8, respectively,p = 0.012) but no statistically significant relationship was seen between the expression of c-kit proto-oncogene product and other clinicopathological parameters of breast cancer, including histologic type, tumor size, lymph node metastasis, distant metastasis, stage, progesterone receptor, c-erbB-2 expression, menopausal status and age of the patient (p > 0.05).
  • CONCLUSIONS: Our results show that a high level of c-kit expression occurs frequently in invasive breast cancer, and its expression is associated with ER but unrelated to other clinico-pathological variables.
  • [MeSH-major] Breast Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848740.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


45. Kamate B, Traore CB, Diallo D, Foko I, Sangare F, Malle B, Coulibaly B, Mounkoro N, Bayo S: [Epidemiology and morphology of breast benign tumors in Mali: about 186 cases]. Mali Med; 2008;23(3):36-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology and morphology of breast benign tumors in Mali: about 186 cases].
  • [Transliterated title] Epidemiologie et morphologie des tumeurs benignes du sein au Mali: a propos de 186 cas.
  • BACKGROUND: Mammary tumors are frequent.
  • Benign tumors are more frequent, and are characterized by a possibility of recurrence or malignant transformation.
  • The aim of this study was to describe the epidemiological and morphological characteristics of breast benign tumors.
  • The study had concerned all benign tumors confirmed by histology.
  • FINDINGS: In total, 186 benign tumors were diagnosed over 611 mammary pathologies (30.44%).
  • The main complaint was feeling a nodule in the breast (91.9%).
  • The most affected breast was the right side (50.8%).
  • Tumor sizes were variable, and the color changed through white to yellow.
  • Histological aspects were: fibroadenoma (72%), lipoma (8.6%), tubular adenoma (5.9%), papilloma (5.4%), lactating adenoma (3.8%), phyllodes tumor (3.8%), and syringomatous tumor (0.5%).
  • CONCLUSION: Benign tumors are frequent in mammary pathology.
  • The patients need a follow-up because of the recurrence or the malignant transformation of these tumors.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617151.001).
  • [ISSN] 1993-0836
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  •  go-up   go-down


46. Larrey D, Bozonnat MC, Kain I, Pageaux GP, Assenat E: Is chronic hepatitis C virus infection a risk factor for breast cancer? World J Gastroenterol; 2010 Aug 7;16(29):3687-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is chronic hepatitis C virus infection a risk factor for breast cancer?
  • AIM: To evaluate the prevalence of breast tumors in adult females with chronic hepatitis C virus (HCV) infection.
  • Participating patients were prospectively questioned during consultation about past breast history and follow-up by mammography.
  • RESULTS: Breast carcinoma was recorded in 17/294 patients with HCV infection (5.8%, 95% CI: 3.1-8.4) vs 5/107 control patients (4.7%, 95% CI: 0.67-8.67).
  • Benign tumors of the breast (mastosis, nodules, cysts) were recorded in 75/294 patients with HCV infection (25.5%, 95% CI: 20.5-30.5) vs 21/107 (19.6%, 95% CI: 12.1-27.1) in the control group.
  • In patients over 40 years, the results were, respectively, as follows: breast cancer associated with HCV: 17/266 patients (6.3%, 95% CI: 3.4-9.3) vs 5/95 patients (5.2%, 95% CI: 0.7-9.7) in the control group; benign breast tumors: 72/266 patients with HCV infection (27%, 95% CI: 21.7-32.4) vs 18/95 patients (18.9%, 95% CI: 11-26.8) in the control group; no breast lesion 177/266 (66.5%, 95% CI: 60.9-72.2) in patients with HCV infection vs 72/95 (75.7%, 95% CI: 67.1-84.4) in the control group.
  • CONCLUSION: These results suggest that chronic HCV infection is not a strong promoter of breast carcinoma in adult females of any age.
  • [MeSH-major] Breast Neoplasms / etiology. Breast Neoplasms / virology. Hepatitis C, Chronic / complications


47. Umanah IN, Akhiwu W, Ojo OS: Breast tumours of adolescents in an African population. Afr J Paediatr Surg; 2010 May-Aug;7(2):78-80
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumours of adolescents in an African population.
  • BACKGROUND: Tumours of the breast are uncommon in childhood and adolescence.
  • Patients in this age group often require a different approach to diagnosis and treatment.
  • The purpose of this study is to highlight the clinicopathologic features of breast tumours in adolescents in a Nigerian city.
  • MATERIALS AND METHODS: Eighty-four breast tumour materials from patients aged 10-19 years were analyzed over a 10-year period at the Department of Pathology, University of Benin Teaching Hospital (UBTH), Benin City, Edo State, Benin City, Nigeria.
  • RESULTS: A majority of the breast tumours were benign.
  • Fibroadenoma was the most common tumour with 46 cases (54.8%), followed by fibrocystic changes with 15 cases (17%).
  • Histologically, most tumours were indistinguishable from the adult types.
  • CONCLUSION: Fibroadenoma is the most common breast tumour in adolescents in Benin City, Nigeria.
  • Breast cancer and male breast tumours are rare in this age group.
  • Routine complete physical examination of children and adolescents should include breast examination.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms, Male / pathology. Fibroadenoma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431215.001).
  • [ISSN] 0974-5998
  • [Journal-full-title] African journal of paediatric surgery : AJPS
  • [ISO-abbreviation] Afr J Paediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


48. Heneghan HM, Martin ST, Casey M, Tobbia I, Benani F, Barry KM: A diagnostic dilemma in breast pathology--benign fibroadenoma with multinucleated stromal giant cells. Diagn Pathol; 2008;3:33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A diagnostic dilemma in breast pathology--benign fibroadenoma with multinucleated stromal giant cells.
  • Fibroadenomas are common benign breast tumours that display a characteristic pathological morphology, although several epithelial and stromal variations exist.
  • A very rare histological finding is the presence of multinucleated giant cells throughout the stroma of a benign fibroadenoma.
  • Cells of this type, which are more commonly found incidentally within the interlobular stroma of breast tissue, are benign and should not be mistaken for malignant cells on microscopic examination.
  • The presence of this unusual cell type in the stroma does not alter the prognosis of otherwise benign lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Pathol. 2008;3:1 [18177503.001]
  • [Cites] Diagn Pathol. 2006;1:1 [16759425.001]
  • [Cites] Acta Cytol. 1997 Mar-Apr;41(2):321-6 [9100761.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):716-20 [9622693.001]
  • [Cites] Diagn Cytopathol. 2005 Oct;33(4):246-51 [16138376.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):66-9 [8807255.001]
  • [Cites] J Cell Biol. 1996 Aug;134(4):971-83 [8769421.001]
  • [Cites] Am J Clin Pathol. 1995 Jun;103(6):685-9 [7785651.001]
  • [Cites] Annu Rev Biochem. 1994;63:345-82 [7979242.001]
  • [Cites] Histopathology. 1992 Feb;20(2):99-106 [1559675.001]
  • [Cites] Am J Surg Pathol. 1986 Nov;10(11):823-7 [3022614.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):74-8 [6303554.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):313-6 [6587706.001]
  • [Cites] Cancer. 1979 Oct;44(4):1305-8 [227561.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):383-9 [474518.001]
  • [Cites] Diagn Cytopathol. 2004 Jun;30(6):396-400 [15176026.001]
  • [Cites] Breast. 2001 Jun;10(3):231-6 [14965590.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):951-4 [12461066.001]
  • [Cites] Acta Cytol. 2002 Sep-Oct;46(5):855-63 [12365219.001]
  • [Cites] Acta Cytol. 2002 May-Jun;46(3):535-9 [12040649.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):768-75 [11787849.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):64-6 [10882247.001]
  • [Cites] Pathology. 2001 May;33(2):153-6 [11358046.001]
  • [Cites] Acta Cytol. 2001 Jul-Aug;45(4):593-8 [11480724.001]
  • (PMID = 18673528.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2526983
  •  go-up   go-down


49. Strumylaite L, Bogusevicius A, Ryselis S, Pranys D, Poskiene L, Kregzdyte R, Abdrachmanovas O, Asadauskaite R: [Association between cadmium and breast cancer]. Medicina (Kaunas); 2008;44(6):415-20
Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between cadmium and breast cancer].
  • Cadmium is a known human lung carcinogen, although some studies indicate a link between cadmium exposure and human breast cancer.
  • The objective of this study was to assess cadmium concentration in breast tissue samples of patients with breast cancer and benign breast tumor.
  • The concentration of cadmium was determined in breast tissue samples of 21 breast cancer and 19 benign tumor patients.
  • Two samples of breast tissue from each patient, i.e. tumor and normal tissue close to tumor, were taken for the analysis.
  • RESULTS. In patients with breast cancer, the mean cadmium concentration was 33.1 ng/g (95% CI, 21.9-44.4) in malignant breast tissue and 10.4 ng/g (95% CI, 5.6-15.2) in normal breast tissue (P=0.002).
  • In patients with benign tumor, the corresponding values were 17.5 ng/g (95% CI, 8.4-26.5) and 11.8 ng/g (95% CI, 5.1-18.5) (P=0.3144).
  • There was a statistically significant difference in cadmium concentration between malignant and benign breast tissues (P=0.009).
  • CONCLUSION. The data obtained show that cadmium concentration is significantly higher in malignant breast tissue as compared with normal breast tissue of the same women or benign breast tissue.
  • Further studies are necessary to determine the association between cadmium concentration in malignant breast tissue and estrogen receptor level, and smoking.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Breast / chemistry. Breast Neoplasms / chemistry. Cadmium / analysis. Carcinoma in Situ / chemistry. Carcinoma, Ductal, Breast / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18660635.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 00BH33GNGH / Cadmium
  •  go-up   go-down


50. Sarrabayrouse M, Loustau H, Mayer HF: Versatility of the 360 degrees periareolar approach for the treatment of mammary pathology. Aesthetic Plast Surg; 2006 Jan-Feb;30(1):9-14; discussion 15
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2001, the authors published the 360 degrees periareolar approach as a new method for breast augmentation in patients with small nipple-areolar complex diameters.
  • Since its implementation, results have been highly satisfactory, encouraging the authors to expand its indication to other mammary pathologies such as tubular breasts, benign breast tumors, and gynecomastia, conditions for which this method also has proved to be useful.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mammaplasty / methods. Nipples / surgery
  • [MeSH-minor] Adolescent. Adult. Breast Implants. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402158.001).
  • [ISSN] 0364-216X
  • [Journal-full-title] Aesthetic plastic surgery
  • [ISO-abbreviation] Aesthetic Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Chang RF, Wu WJ, Moon WK, Chen DR: Automatic ultrasound segmentation and morphology based diagnosis of solid breast tumors. Breast Cancer Res Treat; 2005 Jan;89(2):179-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automatic ultrasound segmentation and morphology based diagnosis of solid breast tumors.
  • Ultrasound (US) is a useful diagnostic tool to distinguish benign from malignant masses of the breast.
  • A high performance breast tumors computer-aided diagnosis (CAD) system can provide an accurate and reliable diagnostic second opinion for physicians to distinguish benign breast lesions from malignant ones.
  • The potential of sonographic texture analysis to improve breast tumor classifications has been demonstrated.
  • The disadvantages of these systems which use texture analysis to classify tumors are they usually perform well only in one specific ultrasound system.
  • While Morphological based US diagnosis of breast tumor will take the advantage of nearly independent to either the setting of US system and different US machines.
  • In this study, the tumors are segmented using the newly developed level set method at first and then six morphologic features are used to distinguish the benign and malignant cases.
  • The support vector machine (SVM) is used to classify the tumors.
  • There are 210 ultrasonic images of pathologically proven benign breast tumors from 120 patients and carcinomas from 90 patients in the ultrasonic image database.
  • The ultrasonic images are captured at the largest diameter of the tumor.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Processing, Computer-Assisted. Ultrasonography / methods
  • [MeSH-minor] Adolescent. Adult. Automation. Databases, Factual. Diagnosis, Differential. False Negative Reactions. Female. Humans. Middle Aged. Observer Variation. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692761.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Netherlands
  •  go-up   go-down


52. Mottolese M, Nádasi EA, Botti C, Cianciulli AM, Merola R, Buglioni S, Benevolo M, Giannarelli D, Marandino F, Donnorso RP, Venturo I, Natali PG: Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer. J Cell Physiol; 2005 Jul;204(1):106-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer.
  • To determine whether phenotypic field changes occur in tissues adjacent to carcinoma, we assayed, by immunohistochemistry, the expression of HER-2, p53, Fas, and FasL in 72 breast cancers (BC) and multiple autologous peritumoral tissues (PTTs) sampled up to 5 cm distance and in 44 benign breast tumors (BBTs).
  • Our data suggest that FasL could be a potential novel biomarker of transformation, which may identify, along with HER2 and p53, precursor lesions in a genetically altered breast tissue.
  • [MeSH-major] Antigens, CD95 / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Membrane Glycoproteins / metabolism. Receptor, ErbB-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Breast Diseases / metabolism. Breast Diseases / pathology. Early Diagnosis. Fas Ligand Protein. Female. Humans. Immunohistochemistry. Phenotype

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15622519.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


53. Gönenç A, Erten D, Aslan S, Akinci M, Simşek B, Torun M: Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int; 2006 Apr;30(4):376-80
Hazardous Substances Data Bank. MALONALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease.
  • Changes in the levels of malondialdehyde (MDA), nitrate and nitrite (as an index of nitric oxide production), lipid hydroperoxide (LOH), total antioxidant capacity (TAC), lipids (total cholesterol and triglycerides) and lipoproteins (HDL- and LDL-cholesterol) were estimated in breast cancer patients (n = 15) and benign breast disease (n = 15).
  • Serum and tissue MDA levels were found to be decreased in breast cancer patients compared to the benign group (p < 0.05).
  • In contrast, nitrate and nitrite levels were increased in serum and tissue of the cancer group compared to benign breast disease patients (p < 0.05).
  • Compared to the benign group, tissue TAC levels were elevated in the breast cancer patient group (p < 0.05).
  • Total cholesterol and HDL-cholesterol were elevated in the benign group compared with cancer patients (p < 0.05).
  • These findings support the hypothesis that lipid peroxidation in serum and tissue of benign breast disease is greater than in breast cancer.
  • However, the enhanced levels of nitric oxide may be in response to inflammation in patients with breast cancer.
  • Total antioxidant status is lower in benign tissue than in cancerous tissue, probably to compensate for this elevated free radical production.
  • [MeSH-major] Antioxidants / metabolism. Breast / metabolism. Breast / pathology. Breast Neoplasms / blood. Breast Neoplasms / metabolism. Lipid Peroxidation

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616293.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Lipid Peroxides; 0 / Nitrates; 0 / Nitrites; 4Y8F71G49Q / Malondialdehyde
  •  go-up   go-down


54. Soares Leite D, Lima de Lima PD, Ferreira Leal M, Suchi Chen E, Casartelli C, de Arruda Cardoso Smith M, Rodríguez Burbano R: Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation. Clin Exp Med; 2006 Dec;6(4):166-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation.
  • Fibroadenoma (FA) is a benign breast tumour that occurs in about 25% of women.
  • Cytogenetic studies suggest that numerical chromosomal aberrations may contribute to tumorigenesis, but chromosomal instability is still poorly characterised in breast cancer.
  • The aim of this study was to investigate numerical alterations of chromosome 21 in 15 breast FAs.
  • Classical cytogenetics analysis showed that all cells were diploidies with modal number varying between 43 and 47 chromosomes, and clonal chromosome alterations in 46.7% of tumours.
  • The study of benign proliferations and comparison with chromosome alterations in their malignant counterparts should result in an understanding of the genes acting in cell proliferation alone and those that cause these cells to both undergo malignant transformation and become invasive.
  • [MeSH-major] Aneuploidy. Breast Neoplasms / genetics. Chromosomes, Human, Pair 21 / genetics. Fibroadenoma / genetics. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191108.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


55. Tsushima Y, Takahashi-Taketomi A, Endo K: Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. J Magn Reson Imaging; 2009 Aug;30(2):249-55
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T.
  • To review the published reports concerning the apparent diffusion coefficient (ADC) value evaluation for the differentiation between malignant and benign breast tumors, articles were searched with the inclusion criteria: (a) a 1.5-T unit was used;.
  • (d) ADC values of breast tumors were reported with mean +/- standard deviation (SD).
  • Meta-analysis from 12 articles revealed that the pooled sensitivity and specificity were 0.89 (95% confidence interval [CI], 0.85-0.91) and 0.77 (95% CI, 0.69-0.84), respectively, and that only the maximum b factor correlated with the mean ADC values of malignant and benign tumors, and the noncancerous breast tissue (P< 0.05,P < 0.01,P< 0.05, respectively).
  • In conclusion, ADC evaluation is useful for the differentiation between malignant and benign breast tumors.
  • [MeSH-major] Breast Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19629992.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


56. Branchini G, Schneider L, Cericatto R, Capp E, Brum IS: Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas. Endocrine; 2009 Jun;35(3):459-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas.
  • Fibroadenomas are the most common benign breast tumors, occurring mainly in young women.
  • Their responses to the hormonal environment are similar to those of normal breast tissue, which suggests that steroid receptors may play a role in tumor development.
  • We evaluated the gene and protein expression of progesterone receptors A and B (PRA and PRB) and the protein expression of estrogen receptor alpha (ER-alpha) in fibroadenoma samples, comparing with adjacent normal breast tissue, from 11 premenopausal women.
  • No alterations in the PRs gene and protein expression and the ER-alpha protein expression were observed between the follicular and luteal phases, in normal breast versus fibroadenomas.
  • Protein levels of PRA and PRB were higher in fibroadenomas compared to normal breast tissue (P = 0.038 and P = 0.031), while the PRs mRNA levels were similar in both tissues (P = 0.721 and P = 0.139).
  • There were no differences in ER-alpha protein expression between normal breast tissue and fibroadenomas (P = 0.508).
  • Our data suggest a role of PRs in the growth and development of fibroadenomas, although without alterations of the PRA:PRB ratio in these tumors.
  • The absence of alterations in ER-alpha protein levels could be a characteristic behavior of fibroadenomas, unlike breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Estrogen Receptor alpha / genetics. Fibroadenoma / genetics. Mammary Glands, Human / metabolism. Receptors, Progesterone / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367380.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 0 / progesterone receptor A; 0 / progesterone receptor B
  •  go-up   go-down


57. Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM: Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients. Tumori; 2006 Nov-Dec;92(6):524-30
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.
  • AIMS AND BACKGROUND: This study aims to detect the expression of E-selectin in tissue and the serum level of its soluble form in patients with primary breast cancer and benign breast tumors and to correlate the results with the clinicopathological data of the subjects.
  • Group A comprised 30 patients with primary breast cancer, group B 9 patients with benign breast tumors, and group C 11 healthy control women undergoing reduction mammoplasty.
  • E-selectin gene expression was investigated in breast tissues by PCR techniques and soluble E-selectin was measured in sera by ELISA.
  • It was expressed in 61.5% of patients with grade 2 breast cancer and in 82.4% of patients with grade 3 breast cancer.
  • E-selectin gene expression was detected in 60%, 73.3% and 100% of patients with stage II, III and IV tumors, respectively.
  • It was detected in 81.8% of patients with node-positive primary breast cancer and in 50% of patients with node-negative cancer.
  • E-selectin was found on the membranes of peritumoral endothelial cells while it was not found on breast epithelial cells.
  • They increased significantly with increasing breast cancer stage (P < 0.001) and were significantly higher in patients with lymph node involvement than in patients without node involvement (P < 0.001).
  • CONCLUSIONS: The studied marker showed associations with established prognostic parameters such as lymph node involvement and histological tumor grade.
  • E-selectin can be regarded as a promising strategy in improving tumor therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. E-Selectin / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Diseases / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260494.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E-Selectin
  •  go-up   go-down


58. Gogo-Abite M, Seleye-Fubara D, Jamabo RS: Fibroadenoma coexisting with infiltrating ductal carcinoma--a case report. Niger J Med; 2005 Apr-Jun;14(2):221-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenomas are benign breast tumours that are commonly diagnosed in young women in their 20's and early 30's.
  • Occurrence of malignancy in the breasts of these women is very rare.
  • METHOD AND RESULT: We report a case of an infiltrating ductal carcinoma within an otherwise benign fibroadenoma in a 23-year-old woman.
  • She presented with a lump, approximately 7cm in diameter, in her right breast.
  • CONCLUSION: Fibroadenomas are commonly diagnosed in patients in their 20's when the risk of developing breast cancer is extremely rare.
  • Despite this rarity all excised breast lumps should be subjected to histopathological evaluation in order to avoid a diagnostic pitfall.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083250.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


59. Gallegos B, Pérez-Campos E, Martinez R, Leyva P, Martinez M, Hernández R, Pina S, Hernández C, Zenteno E, Hernández P: O-glycosylation expression in fibroadenoma. Prep Biochem Biotechnol; 2010;40(1):1-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenomas are human benign breast tumors characterized by proliferation of epithelial and stroma cells of the terminal ductal unit.
  • With this in mind, we evaluated the expression of glycans in fibroadenoma tissue through immunohistochemistry with antibodies against mucin epitopes (Anti CA15-3 and MUC1), as well as with lectins specific for glycans linked to proteins or lipids, and we compared findings with healthy breast specimens.
  • The lectin from Glycine max recognized equally well duct and stroma cells; this was the only lectin showing co-localization with anti-CA15-3 in healthy and tumor tissues.
  • [MeSH-major] Breast Neoplasms / metabolism. Fibroadenoma / metabolism. Lectins / metabolism. Mucin-1 / analysis. Plant Proteins / metabolism. Polysaccharides / analysis
  • [MeSH-minor] Antibodies / immunology. Artocarpus / chemistry. Breast / cytology. Carbohydrate Sequence. Dolichos / chemistry. Female. Glycosylation. Griffonia / chemistry. Humans. Immunohistochemistry / methods. Molecular Sequence Data. Paraffin Embedding. Soybeans / chemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20024790.001).
  • [ISSN] 1532-2297
  • [Journal-full-title] Preparative biochemistry & biotechnology
  • [ISO-abbreviation] Prep. Biochem. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Lectins; 0 / Mucin-1; 0 / Plant Proteins; 0 / Polysaccharides
  •  go-up   go-down


60. Deyle S, Jörn H, Schmid-Schönbein H, Rath W: [Quantitative and qualitative analysis of the blood flow in breast tumors using power Doppler ultrasound]. Ultraschall Med; 2008 Dec;29 Suppl 5:233-8
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative and qualitative analysis of the blood flow in breast tumors using power Doppler ultrasound].
  • [Transliterated title] Quantitative und qualitative Analysen der Durchblutung von Mammatumoren mittels Power-Doppler-Ultraschall.
  • PURPOSE: Our study was performed to obtain additional information regarding the present diagnostic approaches in breast tumor diagnosis by investigating tumor vessels.
  • MATERIALS AND METHODS: 45 solid breast tumors, including 18 benign and 27 malignant histologically proven cases, were studied using quantitative and qualitative parameters with extracted three-dimensional (3D) diagrams.
  • RESULTS: One of the two quantitative values, the color range, showed a statistical significance for distinguishing between benign and malignant lesions by counting more pixels in malignant cases.
  • We detected differences in the blood flow dynamics with a characteristic flow texture in 89 % of benign lesions and periodic oscillations which were identified with a diagnostic accuracy of 78 % in malignant cases.
  • CONCLUSION: The preliminary results show that the proposed method using power Doppler imaging is feasible and can aid in the classification of breast tumors as benign or malignant.
  • [MeSH-major] Breast / blood supply. Breast Diseases / ultrasonography. Breast Neoplasms / blood supply. Breast Neoplasms / ultrasonography. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773383.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Xu XD, Yao C, Lin Y, Wang LP, Ma LL, Wang SM: [The relationship between expression of macrophage migration inhibitory factor and prognosis of breast cancer]. Zhonghua Yi Xue Za Zhi; 2008 Feb 26;88(8):520-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between expression of macrophage migration inhibitory factor and prognosis of breast cancer].
  • OBJECTIVE: To investigate the expression of macrophage migration inhibitory factor (MIF) in breast cancer and to analyze the relationship between MIF expression and clinicopathological features, tumor microvessel density (MVD), and prognosis.
  • METHOD: The expression of MIF in 121 samples of breast cancer, 20 samples of breast benign tumors, and 20 samples of normal breast tissues were examined by tissue microarray using immunohistochemistry.
  • The values of MVD in the breast cancer samples were examined by immunohistochemistry using anti-CD34.
  • RESULTS: The MIF positive expression rate of the breast cancer tissues was 29.8%, significantly higher than those of the benign tumors and normal breast tissue (P = 0.031).
  • The survival rate of the patients with positive MIF expression in breast tissues was 80.
  • 6%, not significantly different from that of the negative MIF expression group (87.1%, P = 0.171), however, the tumor-free survival rate of the MIF positive expression group was 72.2%, significantly lower than that of the MIF negative group (87.1%, P = 0.029).
  • CONCLUSION: MIF may predict a poor prognostic factor for human breast cancer, and may be used as a novel molecular marker to predicate the progression of breast cancer.
  • Through promoting the secretion of IL-8, MIF participates in the angiogenesis in breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Macrophage Migration-Inhibitory Factors / biosynthesis
  • [MeSH-minor] Age Factors. Female. Follow-Up Studies. Humans. Immunohistochemistry. Interleukin-8 / metabolism. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649765.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Macrophage Migration-Inhibitory Factors
  •  go-up   go-down


62. Ben Hassouna J, Damak T, Ben Slama A, Chargui R, Ben Dhiab T, Khomsi F, Gamoud A, Boussen H, Rahal K: Breast carcinoma arising within fibroadenomas. Report of four observations. Tunis Med; 2007 Oct;85(10):891-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma arising within fibroadenomas. Report of four observations.
  • BACKGROUND: Fibroadenoma is a frequent benign breast tumor affecting young woman.
  • AIM: The purpose of this study was to evaluate the outcome of patients with breast carcinoma arising within adenofibroma and to determine the clinical characteristics and the prognosis of this rare entity.
  • The adjacent parenchyma contained fibrocystic dystrophy lesions associated in one case to intralobular neoplasia lesions.
  • CONCLUSION: Every benign mammary nodule must necessarily be verified surgically to avoid misdiagnosing any carcinomatous area because at this stage its prognosis is better.
  • [MeSH-major] Adenofibroma / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Breast Cyst / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy. Metaplasia. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236815.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


63. Guliato D, de Carvalho JD, Rangayyan RM, Santiago SA: Feature extraction from a signature based on the turning angle function for the classification of breast tumors. J Digit Imaging; 2008 Jun;21(2):129-44
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feature extraction from a signature based on the turning angle function for the classification of breast tumors.
  • Malignant breast tumors and benign masses appear in mammograms with different shape characteristics: the former usually have rough, spiculated, or microlobulated contours, whereas the latter commonly have smooth, round, oval, or macrolobulated contours.
  • Features that characterize shape roughness and complexity can assist in distinguishing between malignant tumors and benign masses.
  • We propose to use a signature based on the turning angle function of contours of breast masses to derive features that capture the characteristics of shape roughness as described above.
  • The methods were tested with a set of 111 contours of 65 benign masses and 46 malignant tumors with different parameters.
  • The best classification accuracies in discriminating between benign masses and malignant tumors, obtained for XR ( TA ), VR ( TA ), CX ( TA ), FD ( TA ), and FDd ( TA ) in terms of the area under the receiver operating characteristics curve, were 0.92, 0.92, 0.93, 0.93, and, 0.92, respectively.
  • [MeSH-major] Algorithms. Breast Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Digit Imaging. 2007 Sep;20(3):223-37 [17021926.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2006;1:2791-4 [17945740.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Dec;18(12):1170-7 [10695529.001]
  • [Cites] Med Biol Eng Comput. 2000 Sep;38(5):487-96 [11094803.001]
  • [Cites] Acad Radiol. 2000 Dec;7(12):1077-84 [11131052.001]
  • [Cites] Med Phys. 2001 Jul;28(7):1455-65 [11488579.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1215-27 [11811822.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1285-92 [11811828.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Sci Am. 1990 Feb;262(2):42-9 [2296715.001]
  • [Cites] Med Phys. 1995 Sep;22(9):1501-13 [8531882.001]
  • [Cites] Med Phys. 1996 Aug;23(8):1337-45 [8873030.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Dec;16(6):799-810 [9533580.001]
  • [Cites] Med Biol Eng Comput. 2006 Aug;44(8):683-94 [16937210.001]
  • [Cites] IEEE Trans Biomed Eng. 2008 Jan;55(1):14-20 [18232342.001]
  • (PMID = 17972137.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3043861
  •  go-up   go-down


64. Feng R, Liu X, Guo Z, Li J: Purification and characterization of 66-kDa glycoprotein from human breast carcinoma. Cancer Sci; 2007 Sep;98(9):1344-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and characterization of 66-kDa glycoprotein from human breast carcinoma.
  • We extracted a 66-kDa glycoprotein (GP-1D8) from breast invasive ductal carcinoma tissues.
  • Immunocytochemical and immunohistochemical analysis revealed strong expression of GP-1D8 protein in the cytoplasm of MCF-7 cells and different types of breast carcinoma tissues, but GP-1D8 is absent in normal breast and benign breast tumor tissues.
  • This is the first time human breast carcinoma tissues and MCF-7 cells have been shown to express a 66-kDa glycoprotein similar to human albumin precursor.
  • [MeSH-major] Biomarkers, Tumor / isolation & purification. Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Glycoproteins / isolation & purification. Neoplasm Proteins / isolation & purification
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Peptide Fragments / chemistry. Protein Precursors / chemistry. Serum Albumin / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640306.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / Serum Albumin
  •  go-up   go-down


65. Szubert Z, Sobala W: [Health reasons for work disability among municipal transport drivers]. Med Pr; 2005;56(4):285-93
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases of the musculoskeletal system were major causes of sickness absence among female tram drivers (24%), whereas malignant and benign neoplasms of breast and uterine myoma in 24% of female transport service workers.
  • CONCLUSIONS: The results of the analysis are in agreement with the literature findings and provide explicit evidence that employment in the municipal transport system is the risk factor responsible for the development of serious diseases such as musculoskeletal disorders and neoplasms.
  • [MeSH-major] Disabled Persons / statistics & numerical data. Occupational Diseases / diagnosis. Occupational Diseases / epidemiology. Transportation
  • [MeSH-minor] Aged. Cardiovascular Diseases / diagnosis. Cardiovascular Diseases / epidemiology. Disability Evaluation. Female. Health Status. Humans. Male. Middle Aged. Movement Disorders / diagnosis. Movement Disorders / epidemiology. Poland / epidemiology. Risk Factors. Severity of Illness Index. Urban Population / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Disabilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457365.001).
  • [ISSN] 0465-5893
  • [Journal-full-title] Medycyna pracy
  • [ISO-abbreviation] Med Pr
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


66. Zheng YF, Kong HW, Xiong JH, Lv S, Xu GW: Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clin Biochem; 2005 Jan;38(1):24-30
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance and prognostic value of urinary nucleosides in breast cancer patients.
  • OBJECTIVE: Thirteen urinary nucleosides, primarily degradation products of tRNA, were evaluated as potential tumor markers for breast cancer patients.
  • DESIGN AND METHODS: The micellar electrokinetic chromatography (MEKC) method has been used to analyze the urinary nucleosides in 41 healthy controls, 20 patients with benign breast tumors, and 26 breast cancer patients.
  • RESULTS: Urinary nucleoside concentrations of breast cancer patients were found to increase significantly compared to those of patients with benign breast tumors and healthy controls.
  • By using 13 nucleoside concentrations as data vectors for principal component analysis (PCA), 73% (19/26) of breast cancer patients were correctly identified from healthy controls, while only 20% (4/20) of patients with benign breast tumors were indistinguishable from breast cancer patients.
  • The mean level of all forms of urinary nucleosides in patients with metastatic breast cancer was higher than that in patients with primary breast cancer.
  • CONCLUSION: The results indicate that urinary nucleosides may be useful as tumor markers for breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Nucleosides

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607313.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleosides
  •  go-up   go-down


67. Satish Rao BS, Krishnanand BR, Krishan A: Androgen & vitamin D nuclear receptor expression in archival breast tumour samples. Indian J Med Res; 2006 Jan;123(1):73-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen & vitamin D nuclear receptor expression in archival breast tumour samples.
  • BACKGROUND & OBJECTIVE: Breast tumour cells have receptors for androgen and vitamin D and their clinical significance is not completely understood.
  • Therefore, the present study was undertaken to analyze androgen and vitamin D receptor levels in human primary infiltrating ductal breast carcinomas (IDC) and benign breast tumour archival samples and to find out their correlation, if any, with the clinical findings.
  • METHODS: Paraffin blocks of benign and malignant breast tumours were sectioned, deparaffinized, and nuclei released by pepsin digestion.
  • RESULTS: Androgen receptor positive nuclei ranged from 16-66 per cent in the IDC tumours as compared to 36-67 per cent in the benign tumours.
  • Based on flow cytometric comparison of AR expression in AR positive and negative cell lines established earlier, 24 of 28 tumours from postmenopausal women were AR positive compared to all benign tumours and 32 of 33 tumours from pre-menopausal patients.
  • Vitamin D receptor positive nuclei ranged from 14-89 and 2-75 per cent in IDC and benign tumours, respectively.
  • All pre- or post-menopausal tumours were VDR positive as compared to 10 of 15 benign tumours that were VDR positive.
  • No correlation was seen between nuclear androgen and vitamin D receptor expression of the IDC or benign tumours.
  • No statistically significant correlation was found between nuclear receptor expression (per cent positive nuclei or antigen density) with that of tumour stage, lymph node status, tumour grade, patient age or menopausal status.
  • The expression of AR and VDR and the antigen density in the nuclei of the archival breast tumour samples were highly variable because of the tumour heterogeneity.
  • Future studies with fresh biopsy samples of tumour on AR and VDR levels and their up- or down-regulation may be useful while stratifying the patients for hormonal therapy.
  • [MeSH-major] Breast Neoplasms / chemistry. Receptors, Androgen / analysis. Receptors, Calcitriol / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16567872.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Calcitriol
  •  go-up   go-down


68. Tang Y, Wang L, Zhang P, Wei H, Gao R, Liu X, Yu Y, Wang L: Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol; 2010 Dec;17(12):1903-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
  • Mucin 1 (MUC1), a tumor-associated antigen, is a transmembrane glycoprotein expressed by normal epithelial cells and overexpressed by carcinomas of epithelial origin.
  • Autoantibodies against MUC1 are often found in circulation, either free or bound to immune complexes, which might contribute to limit tumor outgrowth and dissemination by antibody-dependent cell-mediated cytotoxicity, and were found favorably predictive of survival in early breast cancer patients.
  • The results showed that more patients with benign breast tumors (P = 0.001) and breast cancer patients before primary treatment (P = 0.010) were found to have anti-MUC1 IgG than healthy women; anti-MUC1 IgG before primary treatment was found more than after primary treatment (P = 0.016) in breast cancer patients.
  • Furthermore, we found that circulating anti-MUC1 antibodies may still bind MUC1 shed into blood in stage IV breast cancer, which can support the use of MUC1-target immune therapy strategies.
  • [MeSH-major] Autoantibodies / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / immunology. Mucin-1 / immunology. Recombinant Proteins
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay / methods. Escherichia coli / genetics. Female. Humans. Middle Aged. Sensitivity and Specificity. Tandem Repeat Sequences

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 1;96(9):3147-53 [11049996.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):589-94 [10673204.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):1-11 [11759823.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1217-22 [11953875.001]
  • [Cites] Eur J Cancer. 2002 Jun;38(9):1189-93 [12044504.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):97-100 [12455059.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1130-9 [12966437.001]
  • [Cites] Breast Cancer Res Treat. 2003 Oct;81(3):195-207 [14620915.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Urologe A. 1990 Mar;29(2):77-86 [2158684.001]
  • [Cites] Immunol Lett. 1993 Feb;35(2):163-8 [7685318.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2856-60 [7514493.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1325-31 [8869094.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12492-4 [9139698.001]
  • [Cites] Tumour Biol. 1998;19(3):186-95 [9591045.001]
  • [Cites] J Gastroenterol. 1998 Jun;33(3):354-61 [9658314.001]
  • [Cites] Cancer Immunol Immunother. 1998 Jul;46(5):245-52 [9690452.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):570-1 [16164922.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1324-36 [16619287.001]
  • [Cites] BMC Cancer. 2006;6:253 [17064405.001]
  • [Cites] Histol Histopathol. 2007 Aug;22(8):905-22 [17503348.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3060-9 [18483372.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):735-44 [18594319.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1357-63 [18561323.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):574-83 [10653872.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):112-20 [11471893.001]
  • (PMID = 20876819.001).
  • [ISSN] 1556-679X
  • [Journal-full-title] Clinical and vaccine immunology : CVI
  • [ISO-abbreviation] Clin. Vaccine Immunol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ PMC3008176
  •  go-up   go-down


69. Solai F, Nardo T, Patrizi G, Annessi M, Santulli M, Amabile MI, Vasaturo F: [Comparison of plasma matrix metalloproteases 2, 3, 9 in breast carcinomas and fibroadenomas]. G Chir; 2010 Aug-Sep;31(8-9):365-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of plasma matrix metalloproteases 2, 3, 9 in breast carcinomas and fibroadenomas].
  • [Transliterated title] Confronto dei valori plasmatici delle metalloproteasi della matrice 2, 3, 9 in pazienti con carcinomi e fibroadenomi mammari.
  • Tumor cell infiltration causes the remodelling of peritumoral tissues, determined by an increased lytic activity of extracellular matrix exerted by the neoplastic invasive phenotype.
  • Among the principal lytic enzymes produced by tumor cells and mainly involved in invasion process there are the matrix metalloproteases (MMPs).
  • The Authors compared the plasmatic values of MMPs 2, 3, 9 from patients with breast carcinomas and fibroadenomas in order to evaluate whether there was a significant difference between the two groups of patients.
  • MMPs 2, 3, 9 values were quantified by ELISA test from plasma collected 24 hours before surgery in 50 breast carcinomas and 30 fibroadenomas.
  • MMP2 mean value from the patients with carcinomas resulted significantly higher as compared to that from the patients with fibroadenomas; while for MMP 3 and 9 mean values was not possible to find a significant difference between the two groups of malignant and benign breast tumors.
  • These data confirm the main role played by MMPs during the tumor invasion process.
  • Therefore, it is possible to propose the future inclusion of MMP2 test, together to other biological and clinical data, for prognostic evaluation of neoplastic breast lesions.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / enzymology. Carcinoma / enzymology. Fibroadenoma / enzymology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 3 / blood. Matrix Metalloproteinase 9 / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843437.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


70. Poh MM, Ballard TN, Wendel JJ: Beckwith-Wiedemann syndrome and juvenile fibroadenoma: a case report. Ann Plast Surg; 2010 Jun;64(6):803-6
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Beckwith-Wiedemann syndrome (BWS) is a complex overgrowth disorder usually recognized at birth.
  • Children diagnosed with BWS, particularly those with hemihypertrophy, experience an increased risk of developing benign and malignant tumors.
  • This case report presents a 12-year-old girl with BWS and hemihypertrophy who rapidly developed enlarging, asymmetric tumors of bilateral breasts.
  • Few cases of patients with BWS and benign breast tumors exist in the literature.
  • The differential diagnosis of breast tumors in the adolescent female is described.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / genetics. Breast Neoplasms / genetics. Breast Neoplasms / surgery. Fibroadenoma / genetics. Mammaplasty / methods

  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20506580.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


71. Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ, Hsieh FJ: SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J; 2010 May-Jun;16(3):305-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.
  • The purpose of this study was to characterize the immunohistochemical distribution of secreted protein acidic and rich in cystein (SPARC) in benign and malignant breast tumors of different histologic types and define its association with the outcome of invasive ductal carcinoma (IDC) patients.
  • A total of 286 samples of benign and malignant breast lesions between 1994 and 2005 were retrieved from National Taiwan University Hospital.
  • Secreted protein acidic and rich in cystein was not expressed in benign breast phylloides and all benign breast tumors, while expressed in 17.2% of IDC, 85% of metaplastic carcinoma of the breast (MCB), and all malignant breast phylloides.
  • Individuals with positive SPARC expression had 2.34 times higher hazard of death compared with those with negative SPARC expression after adjusting for factors including positive lymph node, TNM tumor stage, estrogen receptor, and progesterone receptor.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Osteonectin / analysis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. Proportional Hazards Models

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210803.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Osteonectin
  •  go-up   go-down


72. Shen C, Hu L, Xia L, Li Y: The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem; 2009 Feb;42(3):194-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR.
  • OBJECTIVES: To develop a specific, reliable assay for detecting circulating tumor cells (CTC) in peripheral blood of breast cancer patients.
  • DESIGN AND METHODS: 94 breast cancer patients, 35 patients with benign breast tumor, 40 healthy individuals, and 25 patients with other solid tumors were evaluated by quantitative real-time reverse transcription-PCR (qRT-PCR) for detecting Survivin, hTERT, and hMAM mRNA in peripheral blood (PB) of breast cancer patients.
  • RESULTS: The sensitivity of Survivin, hTERT, and hMAM mRNA in the PB of breast cancer patients was 36.2%, 59.6% and 33.0%, respectively.
  • Survivin and hTERT were detected in the PB patients with solid tumors other than breast cancer, but hMAM mRNA was only detected in breast cancer patients.
  • CONCLUSIONS: Survivin, hTERT and hMAM mRNA assays are powerful methods for detection of CTC of breast cancer patients.
  • With combination of the three markers for detection of CTC of breast cancer, the parallel test increases the sensitivity.
  • This analysis can offer a simple, noninvasive, and promising adjuvant tool for the early detection of micrometastatic tumor cells in breast cancer patients.
  • [MeSH-major] Breast Neoplasms / diagnosis. Neoplasm Metastasis / diagnosis. Neoplastic Cells, Circulating. RNA, Neoplasm / blood. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022237.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DNA-Binding Proteins; 0 / Inhibitor of Apoptosis Proteins; 0 / MAML1 protein, human; 0 / Microtubule-Associated Proteins; 0 / RNA, Neoplasm; 0 / Trans-Activators; 0 / Transcription Factors; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


73. Liao MN, Chen MF, Chen SC, Chen PL: Uncertainty and anxiety during the diagnostic period for women with suspected breast cancer. Cancer Nurs; 2008 Jul-Aug;31(4):274-83
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncertainty and anxiety during the diagnostic period for women with suspected breast cancer.
  • A possible diagnosis of breast cancer imposes a huge psychological impact on most women, but few studies have addressed uncertainty and anxiety changes at different diagnostic stages in women with suspected breast cancer.
  • Thus, this longitudinal study examined uncertainty and anxiety and predictive factors for uncertainty in women with suspected breast cancer.
  • Data were collected on uncertainty (Uncertainty in Illness Scale) and anxiety (State Anxiety Inventory) from 127 women at 3 times: upon notice of a breast biopsy, before biopsy, and after diagnosis.
  • The results showed that uncertainty and anxiety levels were significantly higher before than after diagnosis.
  • At the 3 data collection times, uncertainty and anxiety were significantly lower for participants diagnosed with benign tumors than for those with malignant diagnoses.
  • Uncertainty was predicted by age, marital status, education level, religious status, family history of benign breast tumor, regular breast self-examination, self-perceived probability of receiving a breast cancer diagnosis, and biopsy result.
  • Therefore, nursing professionals should be aware of the uncertainty and anxiety changes and impact of personal attributes on women with suspected breast cancer during the diagnostic period and provide care programs to alleviate their psychological distress.
  • [MeSH-major] Anxiety / etiology. Biopsy. Breast Neoplasms / diagnosis. Breast Neoplasms / psychology. Stress, Psychological / etiology


74. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP: Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest; 2008 Mar;26(2):159-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast.
  • OBJECTIVE: The objective of this study was to determine if protein-by-products secondary to cancer related oncogenes appear in the saliva of breast cancer patients.
  • One pooled specimen was from healthy women, another pooled specimen from women diagnosed with a benign breast tumor and the other one pooled specimen was from women diagnosed with ductal carcinoma in situ (DCIS).
  • Differential expression of proteins was measured by isotopically tagging proteins in the tumor groups and comparing them to the healthy control group.
  • Forty-nine proteins were differentially expressed between the healthy control pool and the benign and cancer patient groups.
  • Additionally, there may be salivary protein profiles that are unique to both DCIS and fibroadenoma tumors.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Fibroadenoma / metabolism. Neoplasm Proteins / metabolism. Saliva / metabolism. Salivary Proteins and Peptides / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259946.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Salivary Proteins and Peptides
  •  go-up   go-down


75. Huang YL, Lin SH, Chen DR: Computer-Aided Diagnosis Applied to 3-D US of Solid Breast Nodules by Using Principal Component Analysis and Image Retrieval. Conf Proc IEEE Eng Med Biol Soc; 2005;2:1802-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-Aided Diagnosis Applied to 3-D US of Solid Breast Nodules by Using Principal Component Analysis and Image Retrieval.
  • Textural features have been shown to be valuable in tumor diagnosis.
  • This study combines three practical textural features in ultrasound (US) images, i.e. spatial gray-level dependence matrices (SGLDMs), gray-level difference matrix (GLDM) and auto-covariance matrix, to identify breast tumor as benign or malignant.
  • The textural features always perform as a high dimensional vector that is unfavorable to differentiate breast tumors in practice.
  • The principal component analysis (PCA) is used to reduce the dimension of textural feature vector and then the image retrieval technique was utilized to differentiate between benign and malignant tumors.
  • The proposed computer-aided diagnosis (CAD) system differentiates solid breast nodules with a relatively high accuracy in the US imaging and helps inexperienced operators avoid misdiagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17282567.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Giorgi Rossi P, Federici A, Farchi S, Chini F, Barca A, Guasticchi G, Borgia P: The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy. J Med Screen; 2006;13(3):123-8
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy.
  • In this study, we compare the incidences of treatments for benign and malignant neoplasms in the two groups.
  • We linked all incident cases of surgery for benign and malignant breast neoplasms, from the Hospital Information System (1999-2003) to the Mammographic Screening Information System (1999-2001).
  • We calculated incidence, adjusted for age and standardized breast cancer mortality ratio in each area of residence, for benign and malignant neoplasms surgery in non-yet-contacted and contacted woman.
  • RESULTS: The target population in Lazio is 681,000; 116,000 women were contacted during the study period and 3252 malignant and 1566 benign neoplasms were surgically treated.
  • Annual incidence was, respectively, 2.0/1000 and 1.1/1000 for malignant and benign neoplasms in women not contacted, and, respectively, 2.9/1000 and 1.1/1000 in the contacted population.
  • About one-half of the surgeries for benign neoplasms in compliant women were treated against the recommendation of the screening programme.
  • CONCLUSIONS: The implementation of the screening programme did not increase the incidence of treatment for benign neoplasms, and detected 50% more malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / epidemiology. Mammography. Mass Screening. Patient Compliance / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007652.001).
  • [ISSN] 0969-1413
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Gao P, Zhou GY, Zhang QH, Xiang L, Ma C, Yu HP, Yu F: [Expression of mucin 1 and tumor invasiveness in breast carcinoma]. Zhonghua Yi Xue Za Zhi; 2005 Feb 16;85(6):381-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mucin 1 and tumor invasiveness in breast carcinoma].
  • OBJECTIVE: To study the relationship of abnormal expression of mucin 1 with the invasiveness of breast carcinoma cells.
  • METHODS: Immunohistochemistry was used to detect the protein expression of mucin 1 in 5 specimens of juxta-cancerous normal tissues, 20 specimens of benign breast tumors, 35 specimens of early breast carcinoma, 22 specimens of infiltrating cancerous tissues, and 20 specimens of lymph node foci with metastatic breast carcinoma.
  • Human breast cancer cells of the line MCF-7 were cultured and transfected with antisense oligodeoxynucleotide (ASODN) of mucin 1.
  • RESULTS: Top membrane positive expression of mucin 1 was observed in the normal breast tissues and breast benign tumors and whole membrane positive expression of mucin 1 was observed in the 30 of the 35 specimens of early breast carcinoma, 18 of the 22 specimens of breast infiltrating carcinoma, and 17 of the 20 specimens of lymph node metastatic tissues.
  • The mRNA and protein expressions of mucin 1 in the breast carcinoma cells treated with ASODN of mucin 1 were significantly decreased (both P < 0.05).
  • The invasiveness of breast carcinoma cells can be inhibited by the ASODN complementary to the start site of mucin1 mRNA.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Mucins / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor. Female. Humans. Neoplasm Invasiveness. Oligodeoxyribonucleotides, Antisense / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Transfection. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854526.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / RNA, Messenger
  •  go-up   go-down


78. Sheen-Chen SM, Liu YW, Eng HL, Chou FF: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):715-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of hepatocyte growth factor in patients with breast cancer.
  • Elevated hepatocyte growth factor content in tumor tissue was reported to predict a more aggressive biology in non-small cell lung cancer patients.
  • However, there is still limited knowledge about the role of HGF in breast cancer.
  • This study was designed with the aim to elucidate the possible relationship between the preoperative circulating soluble HGF and breast cancer.
  • MATERIALS AND METHODS: One hundred twenty-four consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated.
  • The control group consisted of 35 patients with benign breast tumor (20 with fibrocystic disease and 15 with fibroadenoma).
  • The data on primary tumor staging, age, estrogen receptor status, lymph node status, distant metastases status, histologic grading, and tumor-node-metastasis (TNM) staging were reviewed and recorded.
  • RESULTS: The mean value of serum soluble HGF in patients with invasive breast cancer was 529.05 +/- 123.33 pg/mL and that of control group was 343.00+/- 31.03 pg/mL and the difference was significant (P < 0.001).
  • Furthermore, there were significantly higher serum levels of soluble HGF in patients with negative estrogen receptor (P = 0.035), in patients with poorer differentiated tumor (P < 0.001), in patients with more advanced primary tumor staging (P < 0.001), in patients with more advanced lymph node status (P < 0.001), in patients with distant metastases (P < 0.001), and in patients with more advanced TNM staging (P < 0.001).
  • Thus, preoperative serum soluble HGF levels might reflect the severity of invasive breast cancer and deserve further evaluation.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / pathology. Hepatocyte Growth Factor / blood. Neoplasm Invasiveness
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767355.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


79. Kettenbach J, Helbich TH, Huber S, Zuna I, Dock W: Computer-assisted quantitative assessment of power Doppler US: effects of microbubble contrast agent in the differentiation of breast tumors. Eur J Radiol; 2005 Feb;53(2):238-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-assisted quantitative assessment of power Doppler US: effects of microbubble contrast agent in the differentiation of breast tumors.
  • RATIONALE AND OBJECTIVES: To objectively quantify the effects of a microbubble contrast agent to differentiate breast tumors with power doppler ultrasound and to compare these results with color doppler ultrasound (CD US).
  • RESULTS: Peak color pixel density at contrast-enhanced power Doppler ultrasound was higher for carcinomas than for benign tumors (P < 0.03).
  • Time to peak enhancement was shorter in carcinomas than in benign tumors (P < 0.01).
  • CONCLUSIONS: Quantitative assessment of contrast-enhanced power Doppler ultrasound showed significant differences in malignant and benign breast tumors.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Contrast Media. Diagnosis, Differential. Image Processing, Computer-Assisted. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664287.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


80. Abbasi M, Tarafdari A, Esteghamati A, Vejdani K, Nakhjavani M: Insulin resistance and breast carcinogenesis: a cross-sectional study among Iranian women with breast mass. Metab Syndr Relat Disord; 2010 Oct;8(5):411-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin resistance and breast carcinogenesis: a cross-sectional study among Iranian women with breast mass.
  • Despite existing epidemiologic data concerning the increased incidence of breast cancer in diabetes type 2, the association between insulin resistance and breast carcinogenesis is not yet well defined.
  • In this cross-sectional study, we examined the homeostatic model assessment values of insulin resistance (HOMA-IR) among 82 patients with malignant breast tumor, 48 subjects with benign breast mass, and 838 healthy Iranian women.
  • Age and central obesity-adjusted HOMA-IR values were 3.6 [95% confidence interval (CI), 2.8-4.4], 2.3 (1.7-2.9), and 1.7(1.6-1.8) correspondingly in subjects with malignant breast tumor, those with benign breast mass, and healthy subjects.
  • The interaction effect of age on the association between breast mass (malignant/ benign /no breast mass) with HOMA-IR values was significant [F(54) = 10, P < 0.001, partial eta squared = 0.03].
  • We conclude that the noted linkage between insulin resistance and breast cancer may indicate an underlying pathology of mammary carcinogenesis.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / pathology. Insulin Resistance

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20874423.001).
  • [ISSN] 1557-8518
  • [Journal-full-title] Metabolic syndrome and related disorders
  • [ISO-abbreviation] Metab Syndr Relat Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Insulin
  •  go-up   go-down


81. Bellolio J E, Guzmán G P, Orellana C J, Roa S JC, Villaseca H M, Araya O JC, Tapia E O, Ineda N V: [Diagnostic value of frozen section biopsy during surgery for breast lesions or neoplasms]. Rev Med Chil; 2009 Sep;137(9):1173-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic value of frozen section biopsy during surgery for breast lesions or neoplasms].
  • [Transliterated title] Validez diagnóstica de la biopsia intraoperatoria en cirugía de lesiones mamarias palpables.
  • BACKGROUND: During the surgical treatment of breast neoplasms (benign or malignant), frozen section biopsy is frequently requested to assess the kind of lesion and determine the surgical margins.
  • AIM: To assess the diagnostic yield of frozen section breast biopsy.
  • MATERIAL AND METHODS: AH the pathological reports of frozen section biopsies and definitive biopsies of 337 women aged 26 to 88 years, operated for suspected breast neoplasms between 2002 and 2006, were reviewed.
  • The diagnosis of phyllodes tumor was missed by frozen section biopsy in three cases.
  • CONCLUSIONS: Frozen section biopsy is useful and reliable for cancer detection and margin status assessment in breast cancer surgery.
  • [MeSH-major] Biopsy / methods. Breast Neoplasms / pathology. Frozen Sections / standards. Intraoperative Care / methods

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20011957.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


82. Zhao H, Xu R, Ouyang Q, Chen L, Dong B, Huihua Y: Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions. Eur J Radiol; 2010 Feb;73(2):288-93
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions.
  • OBJECTIVE: To evaluate the significance of contrast-enhanced ultrasound (CEUS) examination in differential diagnosis of malignant and benign breast lesions.
  • METHODS: Seventy-one patients with seventy-six breast tumors are selected randomly.
  • RESULTS: The final histopathological findings distinguished 45 malignant and 31 benign from all of the lesions.
  • In the early phase, CEUS identified 91.1% of malignant tumors characterized by a claw-shaped enhancement, while 83.9% of benign tumors had a homogeneous enhancement, with a statistically significant difference between the two enhancement patterns (chi(2)=43.16, P<0.01).
  • Moreover, contrast medium persistence in the late phase was helpful in the identification of benign and malignant tumors (chi(2)=46.88, P<0.01): contrast medium was present in 88.9% of malignant tumors, while in only 9.7% of the benign tumors.
  • The study showed that various parametric imaging color maps for peak intensity and time to peak were mostly suggestive of malignancy, while quite uniform peak intensity and time to peak of color maps were the characteristic of benign tumors.
  • The study also found that malignant lesions presented with a higher maximum intensity signal than benign ones (P<0.05) on the time-intensity curves.
  • CONCLUSIONS: CEUS cooperating with conventional US shows improved accuracy in differentiating between malignant and benign breast tumors.
  • It could be a reliable diagnostic method of breast lesions.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Enhancement / methods. Phospholipids. Sulfur Hexafluoride. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Humans. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19559551.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


83. Hsiao YH, Huang YL, Liang WM, Lin C, Kuo SJ, Chen DR: Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging. Ultrasound Med Biol; 2009 Mar;35(3):353-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging.
  • The aim of this study was to compare the diagnostic performance of nonharmonic ultrasound (US) and tissue harmonic imaging (THI) using three-dimensional (3D) power Doppler sonographic technique to classify benign and malignant breast tumors by vascularization.
  • All subjects with one or more breast masses were studied with 3D power Doppler US nonharmonic and harmonic technologies.
  • A total of 97 benign and 86 pathologically proven malignant breast tumor images were analyzed.
  • Three histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), on both nonharmonic and harmonic images were calculated for the intratumor and for shells with an outside thickness of 3 mm surrounding the breast lesion.
  • A multilayer perception (MLP) neural network classifier used the vascularity indices to determine whether the breast tumors are benign or malignant.
  • ROC curve analysis used overall age, volume, VI, FI and VFI for both intratumor and shells with an outside thickness of 3 mm surrounding the breast lesions in nonharmonic US and THI.
  • In conclusion, the performance of 3D power Doppler US with respect to the characterization of solid breast masses as benign or malignant was not significantly improved with tissue harmonic imaging.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neovascularization, Pathologic / ultrasonography. Neural Networks (Computer). Ultrasonography, Doppler / methods. Ultrasonography, Mammary / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041173.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M: Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors. Pol Arch Med Wewn; 2008 Sep;118(9):464-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
  • The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
  • OBJECTIVES: In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated.
  • PATIENTS AND METHODS: The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women.
  • RESULTS: Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups.
  • CONCLUSIONS: The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846980.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


85. Kijima Y, Umekita Y, Yoshinaka H, Taguchi S, Owaki T, Funasako Y, Sakamoto A, Yoshida H, Aikou T: Stromal sarcoma with features of giant cell malignant fibrous histiocytoma. Breast Cancer; 2007;14(2):239-44
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of primary giant cell malignant fibrous histiocytoma (GCMFH) of the breast.
  • A 56-year-old Japanese woman presented with a firm mass in the right breast.
  • Mammography and ultrasonography revealed a well-circumscribed and lobulated mass in the upper outer quadrant of the right breast, indicative of a benign breast tumor or mucinous carcinoma.
  • Magnetic resonance imaging revealed a restricted breast tumor without intraductal spread.
  • Breast-conserving surgery with axillary lymph nodes dissection was performed.
  • Histological examination showed primary GCMFH of the breast.
  • No metastases were identified in any of the 15 left axillary lymph nodes resected and surgical margins were free from tumor cells.
  • The tumor was negative for both estrogen and progesterone receptor.
  • To our knowledge, only 30 cases of primary MFH of the breast have been reported in the literature.
  • [MeSH-major] Breast Neoplasms / pathology. Giant Cell Tumors / pathology. Histiocytoma, Malignant Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485912.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


86. Shin JH, Choi HY, Lee SN, Kim YJ: Microinvasive ductal carcinoma arising within a fibroadenoma: A case report. Acta Radiol; 2006 Sep;47(7):643-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenomas are among the most common benign breast tumors in which carcinomas rarely develop.
  • Although a fibroadenoma in an older woman appears benign-looking, the presence of any unusual signs should raise concerns about malignancy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16950696.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


87. Chen CJ, Chang RF, Moon WK, Chen DR, Wu HK: 2-D ultrasound strain images for breast cancer diagnosis using nonrigid subregion registration. Ultrasound Med Biol; 2006 Jun;32(6):837-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-D ultrasound strain images for breast cancer diagnosis using nonrigid subregion registration.
  • Tissue elasticity of a lesion is a useful criterion for the diagnosis of breast ultrasound (US).
  • In this study, we evaluate the accuracy of continuous US strain image in the classification of benign from malignant breast tumors.
  • In general, after compression by the US probe, a soft benign tumor will become flatter than a stiffened malignant tumor.
  • We proposed a computer-aided diagnostic (CAD) system by utilizing the nonrigid image registration modality on the analysis of tumor deformation.
  • One-hundred pathology-proven cases, including 60 benign breast tumors and 40 malignant tumors, were used in the experiments to test the classification accuracy of the proposed method.
  • The A(z) value of the support vector machine based on the four characteristic values used for the classification of solid breast tumors was 0.9358.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Computer-Assisted / methods. Diagnosis, Differential. Elasticity. Female. Humans. Image Processing, Computer-Assisted / methods. Middle Aged. Stress, Mechanical

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785006.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Yen JY, Ko CH, Yen CF, Yang MJ, Wu CY, Juan CH, Hou MF: Quality of life, depression, and stress in breast cancer women outpatients receiving active therapy in Taiwan. Psychiatry Clin Neurosci; 2006 Apr;60(2):147-53
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life, depression, and stress in breast cancer women outpatients receiving active therapy in Taiwan.
  • The aims of the present study were to compare the quality of life (QoL), depression and stress between patients with malignant breast cancer and those with benign breast tumors.
  • The present study also examined the factors related to QoL among the patients who were receiving active treatment for breast cancer.
  • Among the 97 patients participating in the study, 73 patients were diagnosed as having malignant breast cancer (malignant group) and 24 as having benign tumors (benign group).
  • Quality of life, depression and stress were compared between the malignant and benign groups, and the factors related to QoL were also examined.
  • Depression was significantly associated with QoL for both the malignant and benign groups, and the stress from health problem was the most significant predictors for QoL among the malignant group.
  • The breast cancer patients suffered more severe psychological difficulty under active treatment than did the benign group patients.
  • [MeSH-major] Breast Neoplasms / psychology. Breast Neoplasms / therapy. Depression / etiology. Quality of Life / psychology. Stress, Psychological / etiology
  • [MeSH-minor] Adult. Demography. Family / psychology. Female. Health Status. Humans. Middle Aged. Neoplasm Staging. Psychology. Severity of Illness Index. Surveys and Questionnaires


89. Ławicki S, Szmitkowski M, Wojtukiewicz M: The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta; 2006 Sep;371(1-2):112-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
  • BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls.
  • Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
  • METHODS: M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects.
  • RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group.
  • The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage.
  • Statistically significant positive correlation was observed between the M-CSF and CA 15-3 levels.
  • The M-CSF and CA 15-3 diagnostic specificities were 95%.
  • We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage.
  • The M-CSF area under the ROC curve was larger (0.801) than the ROC area of CA 15-3 (0.785).
  • CONCLUSIONS: These results suggest that M-CSF is the good candidate for a breast cancer tumor marker.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631152.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


90. Ma X, Chen C, Xiong H, Li Y: Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls. Breast Cancer Res Treat; 2010 Nov;124(2):453-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.
  • In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradictory and underpowered.
  • To overcome the limitations of individual study and to understand the real situation, we conducted a systematic review and meta-analysis towards the association between TGFB1 L10P polymorphism and breast cancer.
  • Conclusively, this meta-analysis strongly suggests that TGFB1 L10P polymorphism may play a low penetrance role in breast cancer susceptibility in Caucasian.
  • [MeSH-major] Breast Neoplasms / genetics. European Continental Ancestry Group / genetics. Polymorphism, Genetic. Transforming Growth Factor beta1 / genetics
  • [MeSH-minor] Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Neoplasm Invasiveness. Odds Ratio. Phenotype. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349130.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


91. Li YJ, Wen G, Wang Q: [Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan;29(1):70-1, 74
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms].
  • OBJECTIVE: To investigate the differences in the expression of angiogenesis-related molecules between benign and malignant breast neoplasms.
  • METHODS: Thirty breast cancer patients (33 foci) and 30 with benign breast neoplasms (34 foci) were examined for CD34, vascular endothelial growth factor (VEGF) and Flk-1/KDR expressions using immunohistochemistry.
  • RESULTS: In patients with breast cancer, the microvessels densely distributed around the cancer nest.
  • The microvessel density (MVD) in the cancer patients was significantly higher than that in patients with benign tumors (34.48+/-8.34 vs 18.65+/-4.69, P<0.05).
  • In the breast cancer patients, strong VEGF expression was found in the epithelial cells and vascular endothelial cells around the breast carcinoma, and Flk-1/KDR was also strongly expressed in the vascular endothelial cells.
  • The expressions of VEGF and Flk-1/KDR were hardly detectable in the benign tumors.
  • CONCLUSION: VEGF is an important regulatory factor in promoting breast tumor angiogenesis.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218116.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


92. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • Expression level of molecules on tumor cells was analyzed using immunohistochemical method (paraffin embedded slides), and on lymphocytes - by the method of indirect immunofluorescence.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


93. Pu J, McCaig CD, Cao L, Zhao Z, Segall JE, Zhao M: EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells. J Cell Sci; 2007 Oct 1;120(Pt 19):3395-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells.
  • Breast cancers are accompanied by electrical depolarisation of tumour epithelial cells.
  • The electrical changes can be detected on the skin and are used to differentiate malignant from benign breast tumours.
  • Could the electrical signals play a role in metastasis by promoting tumour cell migration?
  • We report that electric fields stimulate and direct migration of human breast cancer cells.
  • Importantly, these effects were more significant in highly metastatic tumour cells than in low metastatic tumour cells.
  • These results suggest that electric signals might play a role in metastasis of breast cancers by enhancing cell migration through the ErbB-signalling pathway.
  • [MeSH-major] Breast Neoplasms. Cell Movement / physiology. Electricity. Receptor, Epidermal Growth Factor / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Enzyme Inhibitors / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Humans. Neoplasm Metastasis. Phosphatidylinositol 3-Kinases / metabolism. Protein-Tyrosine Kinases / metabolism. Rats. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Receptor, ErbB-3 / genetics. Receptor, ErbB-3 / metabolism. rho GTP-Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881501.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 058551; United Kingdom / Wellcome Trust / / 068012
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


94. Garcia-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology; 2005 Jul;47(1):82-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma.
  • AIMS: To characterize the expression pattern of IL-6 and its receptors (IL-6R(alpha) and gp130), to relate this pattern to bcl-2 and bax expression and to elucidate the effects on the proliferation/apoptosis equilibrium in benign conditions and in situ and infiltrating breast cancer.
  • METHODS AND RESULTS: The immunoexpression of IL-6 and its receptors (IL-6R(alpha) and gp130), and their relationship with bcl-2 and bax proteins, were studied in in situ and infiltrating tumours and in benign breast lesions by means of Western blotting and immunohistochemistry.
  • The percentages of samples positive for IL-6, bcl-2 and bax and their immunoreaction densities were higher in in situ carcinomas and infiltrating tumours than in benign lesions; although in in situ lesions were not so high as in infiltrating tumours, except for bax, whose immunoexpression was as weak as in benign conditions, resulting in a bcl-2/bax ratio higher than in infiltrating tumours.
  • CONCLUSIONS: The high expression of IL-6 and its receptors in tumours might be related to the enhanced cell proliferation occurring in breast cancer.
  • The increased bax immunoreactivity observed only in infiltrating tumours, which was not so high as the increase in bcl-2 immunoreactivity, might be interpreted as an attempt to hinder cell proliferation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982327.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / IL6ST protein, human; 0 / Interleukin-6; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Interleukin-6; 0 / bcl-2-Associated X Protein; 133483-10-0 / Cytokine Receptor gp130
  •  go-up   go-down


95. Iwamitsu Y, Shimoda K, Abe H, Tani T, Okawa M, Buck R: Anxiety, emotional suppression, and psychological distress before and after breast cancer diagnosis. Psychosomatics; 2005 Jan-Feb;46(1):19-24
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anxiety, emotional suppression, and psychological distress before and after breast cancer diagnosis.
  • The authors examined the influence of anxiety and emotional suppression on psychological distress in 21 patients with breast cancer and 72 patients with benign breast tumor.
  • The patients with breast cancer who suppressed emotion and had chronically high levels of anxiety felt higher levels of emotional distress both before and after the diagnosis.
  • Such patients need psychological interventions, including encouragement to express and communicate their emotions, immediately after disclosure of the diagnosis to help maintain psychological adjustment in the face of the disease.
  • [MeSH-major] Anxiety / psychology. Breast Neoplasms / psychology. Emotions. Repression, Psychology. Sick Role
  • [MeSH-minor] Adaptation, Psychological. Adult. Affective Symptoms / diagnosis. Affective Symptoms / psychology. Aged. Breast Cyst / psychology. Female. Humans. Internal-External Control. Manifest Anxiety Scale. Middle Aged. Patient Care Team. Personality Inventory

  • Genetic Alliance. consumer health - Anxiety.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765817.001).
  • [ISSN] 0033-3182
  • [Journal-full-title] Psychosomatics
  • [ISO-abbreviation] Psychosomatics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Román-Díaz J, Alayón-Laguer D, Fernández Nelson M, Luis B, Caceres-Perkins W, Conde-Sterling D: Rare benign breast tumor. Bol Asoc Med P R; 2010 Apr-Jun;102(2):50-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare benign breast tumor.
  • We report the case of a female patient with an incidental finding at routine mammography evaluation which consisted of a benign spindle cell tumor, namely Breast Myofibroblastoma.
  • It is important to recognize the benign nature of this neoplasm to prevent extensive mutilating surgical procedures.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939206.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


97. Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat; 2010 Dec;124(3):677-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
  • HAb18G is a recently identified hepatoma-associated antigen and its association with tumor growth, invasion, and angiogenesis has been studied in a variety of tumors.
  • However, its role in the tumor progression of breast cancer has not been explored.
  • HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC).
  • While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01).
  • In an expanded group of 186 BC patients with proper follow up, our previous findings were confirmed: HAb18G expression was significantly associated with local recurrence, distant metastasis and tumor mortality (P < 0.01).
  • We also demonstrated that up-regulated tumor expression of HAb18G was a significant predictor of reduced disease progression-free survival rate and a shorter overall survival, independent of systemic therapies.
  • Further evaluation of this new marker in breast cancer is indicated.
  • [MeSH-major] Antigens, CD147 / analysis. Biomarkers, Tumor / analysis. Breast Neoplasms / immunology. Carcinoma / immunology. Carcinoma, Intraductal, Noninfiltrating / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. China. Disease-Free Survival. Female. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Time Factors. Treatment Outcome. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213083.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136894-56-9 / Antigens, CD147; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


98. Alvarenga AV, Infantosi AF, Pereira WC, Azevedo CM: Assessing the performance of morphological parameters in distinguishing breast tumors on ultrasound images. Med Eng Phys; 2010 Jan;32(1):49-56
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the performance of morphological parameters in distinguishing breast tumors on ultrasound images.
  • This work aims at investigating seven morphological parameters in distinguishing malignant and benign breast tumors on ultrasound images.
  • When nrv and C were taken together with roughness (R), calculated from normalized radial length (NRL), a performance slightly over 83% in distinguishing malignant and benign breast tumors was achieved.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 IPEM. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19926514.001).
  • [ISSN] 1873-4030
  • [Journal-full-title] Medical engineering & physics
  • [ISO-abbreviation] Med Eng Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


99. Gisterek I, Matkowski R, Lacko A, Sedlaczek P, Szewczyk K, Biecek P, Halon A, Staszek U, Szelachowska J, Pudelko M, Bebenek M, Harlozinska-Szmyrka A, Kornafel J: Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res; 2010 Sep;16(3):337-44
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factors a, C and d in human breast tumors.
  • Available evidence suggests that vascular endothelial growth factor (VEGF) a potent regulator of vasculogenesis and tumor angiogenesis may be a predictor of recurrence in breast cancer patients.
  • We sought to determine whether VEGF serum levels (VEGF-A, VEGF-C and VEGF-D) in 377 patients with malignant and benign breast tumors differ and whether there is association between vascular growth factors, clinicopathologic features and prognosis.
  • In Cox model values of angiogenic serum markers and recognized prognostic markers in breast cancer, VEGF-C turned out as independent prognostic factor.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor C / blood. Vascular Endothelial Growth Factor D / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / mortality. Neovascularization, Pathologic / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821158.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


100. Li JR, Li MQ, Li JZ: [Diagnosis and treatment of breast lumps in children]. Zhonghua Yi Xue Za Zhi; 2008 Sep 23;88(36):2556-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of breast lumps in children].
  • OBJECTIVE: To summarize the diagnosis and treatment of breast lumps in children.
  • METHODS: The clinical data of 61 children with breast lumps, 20 with physiological breast masses, 5 male and 15 female, aged 1 - 14, 38 with benign tumors, 1 male and 37 female, aged 10 - 14, 3 with malignant tumors, aged 7 months, and 10 and 13 years. diagnosed and treated 2001 - 2006 were analyzed.
  • The 38 cases with benign tumors all underwent resection, 36 cases were cured and 2 cases recurred.
  • Recurrence was not seen in 2 of the 3 cases of malignant breast tumors, and the patient of leiomyosarcoma died one year after the operation.
  • CONCLUSION: Physiological breast masses in children needn't treatment; mostly enjoy spontaneous cure.
  • The outcomes of benign breast tumors in children are good after operation.
  • Malignant breast tumor is rare, and it is still difficult to predict its prognosis now.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / surgery
  • [MeSH-minor] Adolescent. Breast Diseases / diagnosis. Breast Diseases / surgery. Child. Child, Preschool. Female. Humans. Infant. Male. Remission, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080650.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement